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ABSTRACT 
 
The cells and molecules that comprise the immune system are essential 
for mounting an effective response against microbes.  A successful immune 
response limits pathology within the host while simultaneously eliminating the 
pathogen.  The key to this delicate balance is the correct recognition of the 
pathogen and the appropriate response of immune cells.  Cellular activation 
originates through receptors that relay information about the state of the 
microenvironment to different compartments within the cell.  The rapid relay of 
information is called signal transduction and employs a network of signaling 
mediators such as kinases, phosphatases, adaptor molecules, and transcription 
factors.  IL-2 inducible T cell kinase (Itk) is a non-receptor tyrosine kinase that is 
an integral component of signal transduction downstream of many 
immunoreceptors.  This dissertation describes two distinct pathways that utilize 
Itk in both phases of the immune response. 
T cells use the TCR to sense a multitude of peptide-based ligands and to 
transmit signals inside the cell to activate cellular function.  In this regard, the 
diversity of ligands the T cells encounter can be portrayed as analog inputs.  
Once a critical threshold is met, signaling events transpire in close proximity to 
the plasma membrane to activate major downstream pathways in the cell.  The 
majority of these pathways are digital in nature resulting in the on or off activation 
of T cells.  We find, however, that altering the TCR signal strength that a T cell 
receives can result in an analog-based response.  Here, the graded expression 
of a transcription factor, IRF4, is modulated through the activity of Itk.  We link 
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this graded response to an NFAT-mediated pathway in which the digital vs. 
analog nature has been previously uncharacterized.  Finally, we demonstrate 
that the repercussions of an analog signaling pathway is the altered expression 
of a second transcription factor, Eomes, which is important in the differentiation 
and function of T cells.  These results suggest that Itk is crucial in the modulation 
of TCR signal strength. 
 Mast cells primarily rely on the IgE-bound FcεR1 for pathogen recognition.  
Crosslinking this receptor activates mast cells and results in degranulation and 
cytokine production via an expansive signaling cascade.  Upon stimulation, Itk is 
recruited to the plasma membrane and phosphorylated.  Little else is known 
about how Itk operates inside of mast cells.  We find that mast cells lacking Itk 
are hyperresponsive to FcεR1-mediated activation.  This is most apparent in the 
amount of IL-4 and IL-13 produced in comparison to wild-type mast cells.  
Increased cytokine production was accompanied by elevated and sustained 
signaling downstream of the FcεR1.  Finally, biochemical evidence demonstrates 
that Itk is part of an inhibitory complex containing the phosphatase SHIP-1.  
These results indicate a novel function for Itk as a negative regulator in FcεR1-
mediated mast cell activation. 
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Chapter 1: Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2Opening remarks 
 
One of nature’s crowning achievements, the human body is an intricate 
combination of complex organ systems working in concert to sustain and foster 
life.  It is because of this biological accomplishment we continue to thrive and 
flourish in our environment.  However, we do not subsist alone, nor could we.  
There are millions and millions of different organisms we must co-exist with in 
order to survive.  The vast majority of these co-inhabitants are microorganisms.  
Of the known microbes, most are innocuous to humans, even beneficial, 
providing a source of energy and nutrition.  A small fraction of microbes, 
however, are potentially infectious and may cause disease in humans; we call 
these microbes - pathogens.  Fortunately, evolution has imparted us with an 
immune system to prevent and circumvent the adverse effects of an infection. 
Once a pathogen has breached primary barriers (e.g. skin, saliva, etc.) 
and established an infection by colonizing a niche within a host, the immune 
system is charged with recognition and elimination of the microbe.  The collection 
of tissues, cells, and molecules that constitute the immune system is essential to 
mounting a successful response against foreign invaders.  Typically, activation of 
the immune system by a pathogen results in a two-phased attack initiated by 
innate immune cells and subsequently followed by an adaptive immune 
response.  The goal of this tandem effort is life-long, sterilizing immunity for the 
host against that particular pathogen.  Occasionally, however, the modus 
operandi breaks down and the host is left vulnerable and potential life-
3threatening ailments ensue.  Frequently, these ailments result from such 
disorders as immunodeficiency, autoimmunity, and hypersensitivity (allergy).  In 
order to prevent these conditions or to treat existing immunological diseases, it is 
imperative to understand the mechanisms at play in regulating a proper immune 
response.  This dissertation explores the mechanisms that are involved in the 
proper activation of two specific cell types, T cells and mast cells, which are 
important in an immune response.  The remainder of this chapter is divided into 
three major sections: T cells, Tec kinases, and mast cells.  Following a review of 
the literature, the goals for this dissertation are stated systematically. 
 
Hematopoiesis, T cell development, and the concept of signal strength 
 
 T lymphocytes develop in the thymus where they undergo a step-wise 
maturation into functionally competent naïve cells.  The cells residing in the 
thymus cannot self-renew and therefore require the constant replenishment of 
progenitor cells from the bone marrow.  In the bone marrow, hematopoietic stem 
cells (HSCs) are that constant source of self-renewal that feed the immune 
system’s cellular component.  The derivation of a multipotent progenitor (MPP) 
from HSCs begins the necessary commitment steps for cells seeding the thymus.  
Differentiation of cells into MPPs results in the loss of an ability to self-renew but 
allows for the classic bifurcation of hematopoiesis that is depicted in Figure 1.1  
(1-5).  This is demarcated by the generation of the common  
 
4 
 
Figure 1.1 
 
 
 
 
 
 
 
Figure 1.1 T cell development 
Derived from the hematopoietic stem cell (HSC), the thymic seeding progenitor 
(TSP) migrates from the bone marrow to seed the thymus.  Notch signals 
promote the differentiation to the early thymic progenitor (ETP).  The 
rearrangement of TCRβ, γ , and δ begins at the double negative 2 (DN2) stage.  
DN3 cells undergo β-selection, become γδ T cells, or die.  Rapid proliferation into 
DN4 occurs and TCRα rearrangement occurs at the double positive (DP) stage.  
Positive and negative selection regulates TCR specificity at the DP and single 
positive (SP) stages, respectively.  Carefully scrutinized SP thymocytes mature 
and emigrate from the thymus into the periphery as naïve T cells. 
5myeloid progenitor (CMP) and common lymphoid progenitor (CLP) from the 
MPPa.  In 1997, it was discovered that the CLP was a committed progenitor that 
could give rise to natural killer (NK) cells, B lymphocytes, and T lymphocytes (6, 
7).  It is thought that the CLP seeds the thymus for T cell development, however, 
variations in experimental settings have challenged this notion (8, 9).  
Irrespective of which cell actually seeds the thymus, interaction with the thymic 
stroma results in the differentiation of the most immature T cell progenitors.  
These cells are called early thymic progenitors (ETPs) and are phenotypically 
identified by the expression of c-Kit (CD117) and the IL-7 receptor (CD127), the 
lack of expression of lineage markers (CD8, CD3, TCRβ, TCRγδ, NK1.1, CD11c, 
Mac1, Gr1, B220, CD19, Ter119), and are CD25 negative (10, 11). 
 At this point the ETP remains uncommitted to the T cell lineage, though 
the ability to form other lymphoid populations, like B cells, is greatly diminished.  
A key determinant in T cell commitment is the expression of Notch ligands on 
thymic epithelial cells and Notch receptors on the ETP.  The lack of the receptor, 
Notch1, results in the complete loss of T cells (12, 13).  Once, Notch signaling 
has occurred the ETP can proceed into the textbook differentiation program of T 
cell development.  The cells that enter this developmental phase are said to be 
double negative (DN) for CD4 and CD8 expression yet can be phenotypically 
marked by the expression pattern of CD44 and CD25 (14-16).  Progression from 
the DN1 stage (CD44hi CD25-), where ETPs reside, into the DN2 stage (CD44hi 
CD25+) is highlighted by the accessibility of genes that will form the TCR and the 
a The multipotent progenitor is also thought to give rise to a mast cell precursor.  This will be 
discussed later in this chapter. 
6initial expression of recombination activating genes (RAG) (17, 18).  Because 
developing thymocytes are not synchronous, monitoring the DN2 to DN3 stage 
(CD44lo CD25+) is more like looking at a continuum rather than the stop and go of 
single defined events.  This is not meant to imply that the process is not tightly 
controlled.  In fact, it’s just the opposite.  The proceeding paragraphs will explain 
the regulatory steps in becoming a T cell. 
 The continuous expression of RAG1 and RAG2 during the DN2 to DN3 
transitional phase provides the thymocyte with the ability to rearrange the TCRγ, 
TCRδ, and TCRβ loci (19-21).  In addition to gene rearrangement, this period is 
also a critical point in the commitment of thymocytes to become αβ or γδ T cells.  
A central factor in determining this is the IL-7 receptor.  Signaling through the IL-
7 receptor is thought to be important for opening the TCRγ locus (22-24).  
Furthermore, thymocytes with the highest amount of IL-7 receptor preferentially 
become γδ T cells, whereas those with the lowest amount become αβ T cells 
(10, 25).  The ultimate fate determination between these two T cells is the 
productive rearrangement of TCR genes in conjunction with functions of Id3 (γδ T 
cells) and Notch signaling (αβ T cells) (26-31).  The full commitment to become 
an αβ T cell throughout the DN3 stage begins during β-selection.  This process 
gives the cell several chances to successfully rearrange the genes that will 
comprise the TCR.  The first attempt comes from the TCRβ gene that becomes 
expressed along with a surrogate α -chain (pre-TCRα) and the CD3 signaling 
chains (32-34).  If the TCRβ gene does not undergo successful rearrangement, 
an attempt on the second allele will occur.  A functional TCR complex prompts 
7the cell to cease rearrangement on the TCRβ gene, a process known as allelic 
exclusion.  The DN3 cells that survive β-selection differentiate to the DN4 stage 
(CD44lo CD25-).  During the DN3 to DN4 transition, RAG proteins are down 
regulated and a period of rapid proliferation ensues that will feed the double 
positive (DP) compartment.  DP (CD4+CD8+) cells acquire the surface expression 
of CD4 and CD8 and re-express the RAG proteins to begin working on the TCRα 
gene until a functional protein is generated (11, 35, 36).  It is up to the thymus to 
scrutinize the reactivity and specificity of the productive T cell receptor; and thus 
begins the concept of TCR signal strength. 
 
The concept of signal strength 
 
 When the functionality of a T cell receptor has been verified, the specificity 
of the T cell must next be controlled (37, 38).  This is where the original model of 
TCR signal strength originates (Figure 1.2).  DP cells that demonstrate 
intermediate levels of specificity for host MHC alleles receive signals through the 
TCR to promote their survival and further differentiation.  This is known 
operationally as positive selection.  It is clear that a critical threshold for strength 
of TCR signaling exists because T cells that bind MHC proteins too weakly will 
not receive the necessary anti-apoptotic cues and die by neglect.  Furthermore, 
signals from the TCR also direct the fate of cells that will become CD4 single 
positive (SP) or CD8 SP.  This is accomplished through the actions of a complex  
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Figure 1.2  TCR signal strength in the thymus 
The classic model of TCR signal strength in the thymus adapted from Nature 
Reviews Immunology, 2009, vol. 9, pp. 833-844.  Positive selection ensures that 
intermediate amounts of TCR affinity towards self-pMHC will recognize antigen 
presented in the periphery.  Thymocytes with very little TCR affinity generate low 
TCR signal strength and die by neglect.  Thymocytes receiving strong TCR 
signal strength recognize self-pMHC too well and undergo negative selection. 
  
9transcription factor network, including proteins like Th-POK, Runx, and GATA-3 
(11, 39, 40).  TCR signal strength is thought to be important in this process as 
well.  For example, the differential expression of GATA-3 links TCR signal 
strength to the lineage commitment of CD4 SP or CD8 SP (41, 42).  Strong TCR 
signals result in high levels of GATA-3 expression, which promotes the 
development of CD4 SP cells, whereas weak TCR signals generate less GATA-3 
and drive the lineage toward CD8 SP cells.   
Once DP thymocytes become single positive cells, they are ready to 
undergo a second round of scrutiny, called negative selection.  In this process, 
the presentation of self-peptide embedded within MHC molecules determines 
whether a T cell recognizes that antigen or not.  This is where TCR signal 
strength takes center stage again and dictates that a cell receiving too strong of a 
stimulus will die by apoptosis; whereas a cell that receives an intermediate level 
of stimulation will survive through positive selection.  Another critical threshold 
point for strength of TCR signaling delineates the very fine transition between 
positive and negative selection.  For example, it was elegantly demonstrated that 
small incremental changes (analog) in ligand potency result in dramatic changes 
(digital) in the sensitivity of TCR signal transduction, as shown in the Ras – 
MAPK pathway (43, 44).  High affinity ligands that promoted negative selection 
showed a cellular redistribution of signaling proteins at the plasma membrane.  
On the other hand, cells stimulated with a ligand 1.5 times less potent displayed 
a more sparse distribution pattern of signaling proteins and survived via positive 
selection.  Importantly, this was not due to a lack of signal transduction because 
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all cells expressed CD69.  These experiments demonstrated that small changes 
in ligand quality result in the yes/no event that determines survival or death.   
The collective actions of positive and negative selection, as mediated by 
TCR signal strength, provide the primary means of preventing autoimmunity in 
peripheral tissues.  This is referred to as central tolerance.  Survival of these 
regulatory processes in the thymus renders a mature CD4 or CD8 single positive 
cell functionally competent to serve in the immune system.  It also prompts CD4 
and CD8 T cells to emigrate from the thymus and populate the rest of the body 
as naïve T cells, where they are free to engage peptide-MHC complexes. 
 
T cell activation 
 
The identification of a receptor 
 
 Prior to the 1980’s it was unknown exactly how T cells were activated.  
Many years of research, mostly on allogeneic rejection, helped solidify the notion 
that the lymphoid compartment of the blood was responsible for cytoxicity and 
could provide help to antibody secreting B cells.  Around the turn of 1960’s, a 
series of in vitro studies elegantly demonstrated that the cytotoxicity of T cells 
was specific and likely due to clonal receptors on the cell surface (45-48).  This 
was shown by the incubation of lymphoid cells, obtained from an immunized 
animal, on top of a monolayer of cells containing the immunogen.  Several hours 
following incubation, the monolayer began dying.  Cells that were gently washed 
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off the monolayer, and therefore non-adsorbed, could not replicate the cytoxicity 
when placed on a fresh monolayer.  The adsorbed cells, however, when eluted 
and incubated on a fresh monolayer, were cytotoxic.  It would take another 
decade to actually discover the determinant of this specificity – the T cell 
receptor. 
If the flurry of activity in the literature during the 1980’s showcased 
anything, it was that this decade was a pioneering time for the T cell.  The 
discovery that MHC molecules presented peptides to T cells, the structure of the 
TCR, and the identity of components for the entire T cell antigen receptor 
complex were but a few of the highlights.  As expected then, many groups 
partook in the identification of the T cell receptor, which was spearheaded by the 
use of monoclonal antibodies on a number of human and murine T cell tumor 
lines (37, 49-53).  These studies opened the door to the biochemical, structural, 
and genetic nature of the TCR.  Two groups led, by Tak Mak and Mark Davis, 
independently cloned the TCRβ locus from human and mouse T cells (54-57).  
The presence of variable and constant regions revealed remarkable similarity to 
the BCR and served as the basis for TCR diversity.  Shortly thereafter, Don 
Wiley’s group resolved the crystal structure of MHC Class I and proposed that it 
presented peptides to T cells via a deep, electron dense pocket (58-60).  These 
initial studies laid the groundwork for the molecular mechanism by which T cells 
recognize antigen.  There is, however, one missing component linking this with 
the molecular circuitry inside the cell. 
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 Significant pieces of information pointed towards CD3 as that missing link 
(61, 62).  Monoclonal antibodies directed towards CD3 promoted T cell 
activation.  The presence of long intracellular domains suggested that CD3 was 
an integral part of TCR signal transduction.  A key study using Jurkat mutant T 
cells demonstrated the requirement of CD3 to be co-expressed with the TCR on 
the cell surface of a T cell (63, 64).  Thus all the necessary components for 
examining TCR signaling have been assembled (Figure 1.3). 
 
Proximal TCR signaling 
 
 At present, we understand many of the molecular details involved in TCR 
signal transduction.  As described above, the T cell antigen receptor complex 
consists of two disulfide-linked chains (e.g. α and β), associated in the 
membrane with CD3 signaling chains (i.e. γ , δ, ε, ζ).  These signaling chains 
contain immunoreceptor tyrosine based activation motifs (ITAMs) in the cytosol.  
Crosslinking or ligating the T cell receptor results in the induction of a membrane 
proximal kinase cascade involving three distinct families of non-receptor protein 
tyrosine kinases (PTKs): the Src family, the Syk family, and the Tec family (65, 
66). The initialization of this cascade is mediated by the recruitment of Src family 
kinases, such as Lck and Fyn, to the intracellular portion the TCR complex.  For 
example, Lck is associated with the intracellular domains of the co-receptors 
CD4 and CD8.  CD8 and CD4 bind conserved regions on MHC Class I or MHC 
Class II, respectively, and therefore usher Lck in close proximity to the ITAMs. 
13
Figure 1.3 
 
 
 
Figure 1.3 T cell receptor signal transduction 
The schematic above highlights the important players and pathways in TCR 
signaling.  A more detailed description is in the text.  Briefly, ligation of the TCR 
by pMHC recruits PTKs from three families (Src, Syk, Tec).  Activation of these 
PTKs promotes the assembly of a membrane proximal signaling complex.  This 
complex regulates the generation of secondary messengers, IP3 and DAG, which 
activate major downstream pathways: Ca2+ mobilization, NF-κB, and MAPK 
cascade.  The culmination is transcription factor activation and gene expression. 
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The dephosphorylation of Src family kinases by the phosphatase, CD45, 
facilitates their activation.  ITAMs in the intracellular domains of the TCR complex 
are then phosphorylated by Src family kinases.  The phosphotyrosines in the 
ITAMs provide a docking site for the Syk family kinase, ZAP-70, which in turn, 
gets phosphorylated by Lck.   
The recruitment and activation of Zap-70 is a crucial signaling event that 
determines whether a T cell will be switched on or remain off; there is no 
intermediary at this point.  Once activated, ZAP-70 potentiates the nucleation of a 
large macromolecular complex by phosphorylating the adaptor proteins, LAT and 
SLP-76 (37, 67, 68).  These two adaptor proteins form the scaffold that will 
provide functional access for a number of signaling molecules, including 
enzymes (e.g. PLCγ1, Tec kinases, and PI3K) and adaptors (e.g. Grb2, Gads, 
Nck and Vav) (69, 70).  The activity of PI3K promotes the membrane 
accumulation of PIP3. This increases the probability that PH domain-containing 
proteins, like Itk and PLCγ1, will join the complex.  Multiple interaction sites 
amongst the proteins within this complex act as a molecular glue to maintain 
stability and propagate the signal.  In doing so, Tec family kinases, such as Itk, 
phosphorylate PLCγ1, which in turn cleaves PIP2 into DAG and IP3 (71, 72).  The 
generation of the second messengers, DAG and IP3, mediates the induction of 
three pathways required for the expression of effector genes in T cells.  DAG is 
responsible for evoking two pathways, NF-κB and MAPK, whereas IP3 regulates 
Ca2+ mobilization. 
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The major downstream pathways  
 
 DAG is the membrane bound remnant of PIP2 hydrolysis from PLCγ1 
activity.  The cleavage of PIP2 reveals a docking site for the PKC family member, 
PKCθ, which associates with DAG via a lipid-binding domain (73, 74).  At the 
membrane, PKCθ can phosphorylate CARMA1 to promote the assembly of a 
complex containing Bcl10 and MALT1 (75, 76).  MALT1 is then thought to 
activate the E3 ligase, TRAF6, which polyubiquitinates the regulatory subunits of 
IKK.  Once the regulatory subunits of IKK have been degraded, the catalytic 
portion of IKK then phosphorylates IκB promoting its degradation and the 
subsequent release of NF-κB. NF-κB can then translocate to the nucleus to 
promote the expression of target genes important for T cell function.  
 The DAG – PKCθ tandem is also important in the activation of the guanine 
nucleotide-binding protein (G-protein), Ras.  Ras activation occurs when GTP is 
loaded by guanine nucleotide exchange factors (GEFs), such as son of 
sevenless (SOS) and Ras guanyl nucleotide-releasing protein (RasGRP).  SOS 
is in the same complex as LAT but RasGRP is recruited to the membrane via 
DAG where it becomes phosphorylated by PKCθ.  Both of these GEFs promote 
Ras activation.  However, RasGRP-dependent GTP production catalyzes SOS 
activity thereby promoting a positive feedback loop for Ras activation (69, 77, 
78).  Active Ras is required for the initiation of the first serine/threonine kinase in 
the MAPK cascade, Raf-1 (79, 80).  The MAPK cascade culminates with the 
activation and formation of transcriptional activators, such as AP-1, that induce 
16
target gene expression. 
   In contrast to DAG, the cleavage of PIP2 by PLCγ1 releases IP3 from the 
membrane into the cytosol, where it can liberate intracellular Ca2+ stores from the 
endoplasmic reticulum (ER).  Sensors in the ER membrane detect the depletion 
of intracellular Ca2+, via domains called EF hands, and promote the opening of 
Ca2+ release-activated Ca2+ (CRAC) channels in the plasma membrane, a 
process known as store-operated Ca2+ entry (SOCE) (81-84).  SOCE results in 
the activation of a number of Ca2+ sensitive signaling molecules, including 
calmodulin (CaM).  CaM is another protein that is able to detect high 
concentrations of intracellular Ca2+, via EF hands.  The conformational change 
that occurs in CaM allows it to interact with and promote the enzymatic activity of 
the phosphatase calcineurin.  Calcineurin is then able to dephosphorylate the 
transcription factor NFAT.  Dephosphorylated NFAT is then free to translocate to 
the nucleus and regulate the expression of TCR-dependent genes.  
 
Other pathways 
 
 In addition to the major signaling pathways downstream of the TCR, there 
are several other pathways that are known to be important in the activation of T 
cells.  Stimulation through the TCR promotes cytoskeletal reorganization that 
aids in the polarization of signaling molecules towards the TCR complex (85, 86).  
The most well studied mediators of this pathway are the GEF Vav1 and its 
GTPase effectors Rac1 and Cdc42.  Phosphorylation of Vav1 promotes the 
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activity of Rac1 and Cdc42, which in turn induce F-actin polymerization via 
WASp and WAVE2.  The rearrangement of cytoskeletal actin is important for the 
adhesion of T cells to target cells and migration throughout the body. 
 Another critical moderator of T cell activation is costimulation.  The 
costimulatory molecule, CD28, is a staple in proper T cell activation.  Ligated by 
B7 molecules on APCs, costimulation of T cells via CD28 is the epitomized 
second signal required for T cell activation.  PI3K is one of the major players 
downstream of CD28 signaling.  As mentioned elsewhere, PI3K promotes the 
accumulation of PIP3 in the plasma membrane.  In the context of costimulation, 
however, the activation of PI3K promotes the activity of phosphoinositide-
dependent kinase 1 (PDK1), which phosphorylates its target Akt (62).  Akt is a 
major regulator of T cell activation and is involved in such processes as 
differentiation and survival. 
 
TCR signal strength as a function of activation 
 
 The initial concept of TCR signal strength has been introduced 
superficially as a way to convey the physiological importance (i.e. T cell 
development) of this phenomenon.  A few more words are in order to describe 
some of the parameters that are important in understanding the role of TCR 
signal strength in T cell activation. 
Qualitative and quantitative differences in TCR – pMHC interactions 
influence the T cell response.  Collectively these interactions are referred to as 
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TCR signal strength.  There are a number of ways in which TCR signal strength 
can be modulated experimentally and physiologically.  Many studies utilize 
monoclonal antibodies against CD3 as a surrogate means to activate T cells.  
Even prior to the TCR being cloned and arduously analyzed, experiments using 
anti-CD3 revealed much about the nature of T cell activation.  Crosslinking the 
TCR via increasing amounts of anti-CD3 caused corresponding increases in the 
uptake of tritiated thymidine (87).  More recent studies using anti-CD3 have 
confirmed the idea that T cell activation is either on or off, which is commonly 
referred to as digital signaling.  This was shown by examination of multiple 
aspects of the NF-κB pathway, which revealed that it acts in a digital manner in 
response to TCR ligation (88).  Experimentally, cells analyzed for the activation 
of NF-κB showed that only the proportion of cells responding to TCR stimulation 
changed in response to altered signal strength.  The magnitude of NF-κB 
activation, however, did not vary, indicating the presence of a robust ‘all-or-none’ 
response.  Interestingly, these observations were also made when numerous 
components upstream of NF-κB were examined.  This included PKCΘ 
membrane localization, formation of the BMC complex, and activation of IκK.  
However, the strength at which anti-CD3 elicits its action on the TCR is orders of 
magnitude greater than what a T cell sees under physiological circumstances 
(89).   
Another approach to investigating TCR signal strength is by using pMHC 
complexes known to induce T cell responses in vivo.  In using these TCR 
ligands, the binding parameters of TCR – pMHC can be analyzed in the context 
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of signal transduction.  For example, measurement of TCR – pMHC interaction 
kinetics determined that ligands with slower off-rates induced more extensive 
phosphorylation of the CD3ζ chains (90).  In similar studies, it has been revealed 
that measuring early activation events can sometimes not construe the entire 
story.  In response to weak TCR ligands, the amount of Ca2+ inside the cell takes 
considerably longer to elevate to levels equivalent to strong ligands (91).  The 
limitations of these types of assays aside, they have quantitatively provided us 
with the ability to distinguish the boundaries of T cell activation.   
In addition to studying the potency of TCR – pMHC interactions, a number 
of other factors influence TCR signal strength.  This includes, but is not limited to, 
the density of pMHC presented to a T cell, duration of TCR – pMHC interaction, 
biophysical constraints imposed on the T cell - APC conjugate, and the binding of 
co-receptors and adhesion molecules (92).  Moreover, a T cell’s ability to 
distinguish between different pMHC ligands likely involves the regulatory 
activities of signaling molecules like kinases, which can further modify TCR 
signal strength. 
Numerous examples of T cells utilizing signal strength can be found in the 
literature.  The foremost example, thymic development, has already been 
described.  The strength of TCR signaling also has an important role in regulating 
the in vivo response of CD4 T cells as well as directing the lineage fate of helper 
T cells.  Analysis of tetramer binding approximates the average affinity of TCR – 
pMHC in an antigen-specific CD4 T cell population responding to primary and 
secondary immunizations, and therefore the entire T cell repertoire can be 
20
examined against a given immunogen (93).  Here, it was observed that T cells 
responding to a secondary challenge displayed a greater intensity of tetramer 
binding than T cells from the primary challenge.  This narrowing of the repertoire 
indicates that T cells with a greater affinity towards antigen displayed a selective 
advantage over T cells with a lower affinity. 
One of the central themes in T cell biology is the differentiation of CD4 
helper T cells into effector cells such as TH1, TH2, and TH17 cells.  Differentiation 
of CD4 T cells into these effector subsets is controlled by many factors, most 
notably the cytokine microenvironment (94).  CD4 T cell differentiation occurs in 
the context of TCR stimulation and it is here that TCR signal strength has an 
influence on which lineage the cell will become.  In vitro studies of CD4 T cell 
differentiation suggest that weaker TCR-pMHC interactions preferentially 
promote the generation of IL-4-producing T cells, and thus the generation of TH2 
cells (95).  Conversely, CD4 T cells exposed to strong TCR stimulation become 
TH1 cells producing an abundance of IFN-γ (96).  More recently, T follicular 
helper cells (TFH) appear to also be influenced by TCR signal strength.  In a 
polyclonal population of CD4 T cells, differentiation into the TFH subset is more 
efficient when the cells have a higher affinity towards cognate tetramer than non-
TFH cells (97).  Therefore, a precedent is set whereby the strength of TCR 
stimulation can drastically alter the differentiation fate of CD4 T cells.   
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Consequences of TCR signaling 
 
Controlling CD8 T cell activation and differentiation  
 
The overall goal of TCR signaling is the functional activation of T cells.  T 
cell function manifests as proliferation, differentiation, cytokine secretion, 
cytoxicity, migration, etc.  In order to bridge the gap between the environmental 
input and the functional output of T cells, TCR signaling must initiate a number of 
intracellular processes.  These processes include such modifications as 
cytoskeletal rearrangements, induction of cell cycle, and the mobilization of 
transcription factors that act on specific genes.  Several transcription factors have 
been described above (e.g. NFAT, NF-kB, AP-1, etc.) and these represent the 
initial group of cellular activators responsible for gene expression.  Some of the 
genes that are regulated by this initial group include a second wave of 
transcription factors that are important in facilitating the effector phase of T cell 
activation.   
The T-box transcription factors, T-bet and Eomesodermin (Eomes), are 
two of the most well-characterized regulators from this second tier of transcription 
factors.  They have roles in both CD4 and CD8 T cell activation and 
differentiation.  For example, T-bet is highly expressed in effector CD8 T cells 
that are activated in the context of a pro-inflammatory environment. This was 
demonstrated in Tbx21-deficient mice that fail to develop short-lived effector cells 
(SLECs), defined by reduced IL-7 receptor (CD127) expression and increased 
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levels of surface KLRG1, in response to an LCMV infection (98).  SLECs are the 
predominant effector cell generated during the acute phase of a CD8 T cell 
response to infection.  The other major effector cells generated are the memory 
precursor effector cells (MPECs).  It is thought that this cell type populates the 
pool of memory CD8 T cells that forms upon infection resolution.  As opposed to 
T-bet and SLECs, Eomes is typically associated with CD8 T cells that become 
MPECs (99).  Two important lines of evidence support this notion.  First, Eomes 
was found to preferentially segregate in daughter cells that form MPECs (100, 
101).  Secondly, Eomes expression is suppressed in response to high levels of 
the pro-inflammatory cytokine IL-12, which can induce high levels of T-bet (102).  
Like, T-bet, Eomes expression is controlled by a complex signaling pathway that 
is initiated by the TCR and utilizes inputs from a variety of other pathways (e.g. 
cytokine signaling and costimulation).   
More recently, additional transcription factors, that are regulated at various 
time points following TCR signaling, seem to be important in mediating the 
differentiation of CD8 T cells (103).  Examples include Blimp-1, Bcl6, and TCF-1.  
Similar to T-bet and Eomes, Bcl6 and Blimp-1 share a reciprocal role in the 
differentiation of CD8 T cells.  Blimp-1, like T-bet, appears to control the 
generation of SLECs in numerous models of infection (104-106).  Direct 
regulatory control over Blimp-1 can occur with binding of Bcl6 to the Prdm1 
(Blimp-1) promoter, and vice versa (107).  As such, Bcl6 mediates the expansion 
of memory CD8 T cells.  In models of infection, mice that lack Bcl6 activity exhibit 
a reduction in memory CD8 T cells; whereas transgenic mice that overexpress 
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Bcl6 have elevated numbers of memory CD8 T cells (108).   Similarly, TCF-1 
appears to regulate the formation of MPECs over SLECs.  Mice that are deficient 
in TCF-1 show increases in the SLEC population with concomitant decreases in 
MPECs suggesting that the lack of TCF-1 prohibits the production of MPECs 
(109).  It is believed that TCF-1 acts upstream of Eomes to promote the 
formation of MPECs following infection.  Several experiments support this 
conclusion.  First, the loss of TCF-1 prevents severely diminishes the expression 
of Eomes.  Second, TCF-1 is capable of direct regulation of Eomes by binding 
upstream regulatory elements within the Eomes promoter.  Finally, the lack of 
MPEC formation that occurs in TCF-1 deficiency can be rescued by retroviral 
transduction of Eomes, which restores memory CD8 T cell differentiation.  It is 
currently unclear exactly how these transcription factors control CD8 T cell 
differentiation.  For example, despite the overwhelming amount of evidence to 
suggest that Eomes is responsible for the formation of memory CD8T cells, it 
was recently shown that Eomes deficient T cells could still form a functional 
memory population even after a pathogen had been cleared (110).  Intriguingly, 
however, these cells were not able to efficiently compete with WT T cells in 
mixed bone marrow chimera experiments when challenged with a pathogen.   
 
Tec kinases 
 
 In the late 1940’s, a young boy was admitted to the Walter Reed Army 
Hospital in Washington, D.C. with shaking chills, high fever, arthritic-like pain, 
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and nausea.  He was given a thorough physical examination that yielded few 
additional symptoms.  Blood work showed white blood cell counts that were 
within normal range and a 10-day culture that turned up negative.  Treatment 
with penicillin alleviated the existing symptoms and he was consequently 
discharged.  A couple of weeks later, the boy was readmitted with similar 
symptoms.  Again, he was treated with penicillin and released.  This course of 
hospitalization and release would continue for many months until an attending 
physician, Col. Ogden Bruton, analyzed the serum content by protein 
electrophoresis.  It was discovered that the boy lacked circulating IgG antibodies; 
he was then diagnosed with agammaglobulinemia, a rare x-linked genetic 
disorder b  (112).  Many years later, the genetic basis for x-linked 
agammaglobulinemia (XLA) was identified as Btk, a member of the Tec kinase 
family (113-115). 
 The Tec family is one of the most prominent protein tyrosine kinase (PTK) 
families known and the second largest of the non-receptor variety.  As listed in 
Table 1.1, Tec family kinases are predominantly expressed in hematopoietic 
cells.  Cellular expression is usually overlapping with two or more Tec kinases in 
a given cell (Figure 1.4).  In mice, the five members include: Tec, Btk, Itk, Rlk, 
and Bmx.  They are primarily involved in the signal transduction of several 
receptors in the immune system, most notably the multi-chain immune 
recognition receptor family, or immunoreceptors.  Tec kinases have roles in 
cellular development and activation of immune responses.  This is supported by  
b The boy was eventually treated with adoptive immunotherapy via introduction of exogenous 
IgG, and his clinical manifestations improved (111). 
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Table 1.1 
 
 
 
 
 
Table 1.1 Tec family kinases  
The table above lists the 5 Tec family kinases found in mice.  Several Tec family 
kinases are also known by other names (e.g. Itk was also called Tsk and Emt in 
the early 1990’s).  The full name commonly used in the literature is listed in the 
second column.  The known cellular expression of each family member is listed 
in the third column. 
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Figure 1.4 
 
 
 
Figure 1.4 A representative expression pattern of Tec kinases in the 
immune system 
The expression pattern of Tec family kinases frequently overlaps in many cells of 
the immune system.  The relative amount of expression of each Tec family 
member is represented by the font size.  For example, Itk is the dominant Tec 
family member in T cells, which contain less Rlk and even less Tec.  Mast cells 
express four out of five members with Btk and Itk being co-dominant. 
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in vitro and in vivo experimentation using mouse models (72).  Humans with 
genetic deficiencies in Tec kinases are highly susceptible to recurrent infections 
and increased mortality (116, 117). 
 
Structure of Tec kinases  
 
Close to 20 years ago, molecular cloning identified a multitude of new 
intracellular proteins from immune cells.  These proteins were characterized by a 
catalytic tyrosine kinase region as well as molecular interaction domains like the 
Src-homology (SH) domain and the Pleckstrin-homology (PH) domain (118).  It 
was unclear as to whether or not these proteins constituted a discrete PTK family 
(119).  The cause for such confusion was apparent from the organizational 
structure of modular domains and the high degree of sequence homology with 
Src family kinases (120).  For example, Tec kinases (as shown in Figure 1.5) 
have a catalytic kinase domain and SH domains (i.e. SH2 and SH3) that reside in 
the carboxy-terminus (C-terminus).  Closer inspection of the amino-terminal (N-
terminal) portion determined that these proteins comprise their own family of non-
receptor tyrosine kinases (120, 121).  In the N-terminal region, Tec kinases are 
distinguished from other PTK families by the presence of a PH domain and a Tec 
homology (TH) domain.  The TH domain contains a Zn2+- binding Btk homology 
motif and proline-rich regions (PRR).  Noticeably absent from Tec kinases are 
the N-terminal myristoylation sites and C-terminal regulatory tyrosine residues 
found in Src family kinases (122).  
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Figure 1.5 
 
 
 
 
 
 
 
Figure 1.5 Structural domains of Tec family kinases 
Adapted from Current Opinions in Immunology, 2002, vol. 14, pp. 331-340.  Five 
mammalian kinases of the Tec family are compared with Src kinase, of the Src 
family.  The C-terminal portion of the Tec family contains a high degree of 
homology (kinase, SH2, and SH3 domains) with the Src family.  The N-terminal 
portion of the Tec family houses the Tec homology domains, which contains a 
Btk homology motif and proline-rich regions.  Four of the five members are 
capped with a Pleckstrin homology domain.  Rlk/Txk contains a cysteine string 
that is post-translationally modified.  In comparison, Src, has an N-terminal 
membrane localization motif and a C-terminal regulatory tail. 
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Described above is the general structure of Tec family kinases.  Some 
members have slight variations in the number or position of these regions.  The 
exception to this organizational structure is Rlk/Txk.  Rlk/Txk is a unique member 
that typically contains a cysteine-string motif, which allows for post- translational 
palmitoylation, in place of the PH domain.  Overall, the structural features of the 
N-terminal region appear to be limited to the Tec family tyrosine kinases and, 
therefore, provide a unique mode of regulation in PTKs. 
  
Regulation of Tec kinases 
 
The intramolecular structure of Tec kinases places restrictions on their 
regulation and function.  Well characterized regulatory mechanisms occur 
through components of the N-terminal portion of Tec family kinases (72).  For 
instance, the PH domain plays a critical role in the subcellular localization of the 
Tec kinase Itk.   Here, the PH domain of Itk allows it to become tethered to the 
plasma membrane upon generation of phosphatidylinositol (3,4,5) trisphosphate 
(PIP3) (123, 124).  This means that in a cellular resting state, when the levels of 
PIP3 are low, PH domain-containing Itk is largely cytosolic.  Conversely, when 
levels of PIP3 are high, Itk aggregates at the membrane where kinase activity can 
ensue.  Regulation of these events can be controlled by a number of proteins.  
Upon immunoreceptor ligation (e.g. TCR), phospoinositide 3-kinase (PI3K) 
becomes active and generates PIP3 from the phosphorylation of 
phosphatidylinositol (4,5) bisphosphate (PIP2).  In contrast, phosphatase and 
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tensin homolog (PTEN) can directly counteract PI3K activity by 
dephosphorylating PIP3 under inhibitory or homeostatic conditions (125).  This 
action is instrumental in regulating Itk because PTEN-deficient T cells 
constitutively localize Itk at the plasma membrane.   
This is not the sole means of Tec family kinase regulation via the PH 
domain.  The association of the Tec PH domain with PIP3 at the plasma 
membrane can be influenced by the activity of SH2-containing inositol-5-
phosphatase (SHIP), which also diminishes the amount of PIP3 in the membrane 
(126).  Moreover, this mechanism appears to be mediated through a direct 
interaction between the SH3 domain of Tec and SHIP proteins.   
Another mechanism for the regulation of Tec family kinases through PH 
domains includes a positive feedback loop promoted by Btk in B cells (127).  The 
association of Btk with PI5K, upon BCR activation, promotes co-localization and 
recruitment to the membrane.  Once there, PI5K can generate PIP2 by 
phosphorylating phosphatidylinositol 4-phosphate (PIP).  PI3K can then convert 
this product into PIP3, which in turn promotes the recruitment of more PH 
domain-containing proteins to the membrane.  This feedback loop is negatively 
regulated by SHIP, as ablation of SHIP promotes Btk-mediated BCR activation 
(128, 129).  
Recruitment of Rlk/Txk to the plasma membrane is regulated in a 
completely different manner.  The lack of a PH domain suggests a different mode 
of membrane localization.  The existence of a cysteine-string motif permits the 
constitutive association of Rlk/Txk to the plasma membrane upon post-
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translational palmitoylation.  It has been further shown that association with the 
plasma membrane localizes Rlk/Txk to lipid raft microstructures, which cluster 
together upon immunoreceptor crosslinking (130). 
In addition to the regulation that occurs at the plasma membrane, Tec 
kinases use their other domains to form protein-protein interactions.  Ligation of 
immunoreceptors causes a recruitment of Tec family kinases to the receptor-
signaling complex so that they may relay signals to the rest of the cell.  This type 
of recruitment involves the nucleation of a large macromolecular complex.  In T 
cells, this complex is scaffolded by the adaptor proteins linker for activation of T 
cells (LAT) and SH2-domain-containing leukocyte protein of 76 kDa (SLP-76).  
These two molecules are critically important for Itk to impose its function.  The 
regulation of this event occurs through the specific phosphorylation of tyrosine 
residues on LAT and SLP-76 by the Syk family kinase zeta-chain-associated 
protein kinase 70 (ZAP-70).  The molecular recognition of Itk by SLP-76 and LAT 
is regulated both directly and indirectly.  Indirectly, Itk can associate with LAT 
through the adaptor protein growth factor receptor-bound protein 2 (Grb-2) via 
proline-rich regions in the TH domain (124).  Direct regulation of Itk can occur 
through the SH2 domain.  The importance of the Itk SH2 domain is highlighted in 
a SLP-76 mutant that prevents docking of Itk at Tyr 145, resulting in diminished 
downstream signal transduction (131).  Because the PH domain of Itk is still 
present, the membrane localization of Itk is not ablated, only its kinase activity.    
Kinase activity of the Tec family is initiated by tyrosine phosphorylation on 
a conserved activation loop within the catalytic domain (121).  This results in a 
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conformational change that allows access to substrates (e.g. PLCγ).  Though 
auto-phosphorylation of Tec kinases does occur, the activation loop is actually 
trans-phosphorylated by Src family kinases.  This feature further distinguishes 
the Tec family from the Src family, in which auto-phosphorylation of the activation 
loop does happen.  The auto-activation event that transpires in Tec kinases takes 
place on conserved residues in the SH3 domain and is best documented in Itk 
and Btk (132-134).  The significance of this auto-phosphorylation event is 
unclear, though, as signal transduction is not impaired in B cells, but is 
diminished in T cells.  It is likely that this event is more important in mediating 
protein-protein interactions than direct kinase activity (121).  What is certain is 
that tyrosine phosphorylation of Tec kinases and subsequent conformational 
changes are crucial to proper activation of downstream targets.  
One final major mode of regulation that occurs in Tec family kinases is 
inter- and intramolecular interactions.  This is a mechanism at play during times 
of cellular homeostasis, ensuring that inadvertent kinase activity is not initiated.  
This type of phenomenon is well-documented in the Src family, where C-terminal 
negative regulatory residues stabilize an intramolecular interaction with its own 
SH2 domain (135).  The Tec family, however, fails to possess these 
autoinhibitory sequences and must rely on other means to self-regulate.  In vitro 
experiments have found that the SH3 domain of Tec, Btk, and Itk can interact 
with its adjacent PRR, essentially folding up on itself, to limit binding with other 
proteins (136-139).  It appears likely, however, that intermolecular dimers 
preferentially form.  A model set forth proposes that, with Itk for example, the 
33
intermolecular interaction between SH3 and SH2 domains, and resulting 
homodimer, supersedes that of the intramolecular associations (140).   
Taken together, the information detailed above demonstrates the 
existence of several layers of regulation for Tec family kinases.  This is 
necessary because the Tec family is positioned in such a way as to relay the 
propagation of membrane proximal signaling events to major downstream 
pathways required for cellular activation.  Dis-regulation of Tec kinases leads to 
severe signaling defects in B cells and T cells. 
 
Itk 
 
Several groups cloned Itk in the early 1990’s using degenerate PCR to 
screen for novel tyrosine kinases in hematopoietic cells (141-145).  Most of these 
reports found this newly discovered gene was expressed in T cells and was 
inducible in response to IL-2, hence the name IL-2-inducible T cell kinase.  One 
report found further expression of this gene in mast cells and called it Emt 
(expressed in mast cells and T cells) (143).  What’s known about Itk in mast cells 
is limited and will be discussed at the end of this chapter.  Much of what is known 
about Itk has been derived through in vitro and in vivo studies on murine T cells.  
Itk has been implicated in signaling downstream of the CD2, IL-2 (CD25), CD28, 
and chemokine receptors; its most renowned role, though, is downstream of the 
TCR (146-149). 
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Actions of Itk 
 
The primary substrate of Itk in T cells is PLCγ1.  As described previously, 
the activation of PLCγ is essential for integrating membrane proximal events with 
major downstream signaling pathways.  Accumulation of PIP3 in the plasma 
membrane promotes the aggregation of Itk to the cell surface via the PH domain.  
The SH2, SH3, and TH domains act as a molecular adhesive when they interact 
with adaptor proteins such as LAT, SLP-76, and Grb-2. This forms a large 
macromolecular complex, sometimes referred to as a signalosome (150).  Itk can 
then be activated by the tyrosine phosphorylation of Src family kinases.  The now 
accessible catalytic domain of Itk is then able to specifically phosphorylate 
PLCγ1 (151-153).  This step regulates the production of secondary messengers 
like IP3 and DAG, promoting further signal transduction and gene expression. 
Itk is also involved in other aspects of TCR signaling such as cytoskeletal 
reorganization.  A requirement for multiple domains, including the PH and SH2 
domains, is necessary to induce TCR-mediated actin polymerization (154, 155).   
Subsequently, it was found that Itk could directly interact with Vav, a regulator of 
actin machinery, via its SH2 domain (156).  Interestingly, this event does not 
require the kinase activity of Itk, indicating a novel function for Itk as an adaptor.  
It also indicates that the other modular domains of Itk are not simply required for 
its regulation, but rather are a functional unit in TCR signaling. 
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Itk deficiency 
 
 The clinical relevance of Itk was not fully appreciated until fairly recently 
when two young sisters developed a fatal lymphoproliferative disorder (117).  
These girls suffered from recurrent infections and a general inability to control 
EBV-induced B cell proliferation.  This severe immune dis-regulation was 
genetically mapped to a candidate gene that encoded Itk.  The result of a 
homozygous missense mutation in the SH2 domain of Itk led to unstable protein 
expression in these girls.  Since this initial case, additional carriers of Itk mutant 
alleles have been found and, like human Btk deficiency, the mutations in Itk span 
across the protein (e.g. PH, SH2, and kinase domains) (157).  Unlike Btk, 
however, the mortality associated with Itk deficiency is much higher, and 
treatment requires total replacement of the immune system by hematopoietic 
stem cell transplant (HSCT). 
 The initial body of research on the characterization of Itk carried out in 
vitro has yielded much information about the implicit nature of Itk.  Much more 
was learned about Itk when Itk-deficient mice were made.  The first report of Itk-
deficient mice provided a physiological role for Itk in T cell development, showing 
a partially intact but severely altered T cell repertoire (158).  Phenotypically this 
was demonstrated by an observation in the thymus of fewer total mature 
thymocytes, decreased CD4 T cells, and a skewed CD4:CD8 T cell ratio.  Itk-
deficient T cells had diminished proliferative capacity in response to a mixed 
lymphocyte reaction, mitogen stimulation, and TCR crosslinking.  This defect in T 
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cells lacking Itk was rescued by using PMA and ionomycin, which bypasses 
membrane proximal signaling events.  Moreover, supplementation with 
exogenous IL-2 also restored proliferation.  This genetic ablation of Itk 
corroborated the TCR signaling defect from previous in vitro reports and also 
provided the field with a means to study Itk in vivo.   
The second major report c  using Itk-deficient mice made substantial 
headway into the biochemical mechanism by which Itk exerted its function (159).  
It was here that a significant link between Itk, Ca2+ mobilization, and IL-2 
production was firmly established.  Although intracellular stores of Ca2+ could be 
released, the potentiation of this major pathway by extracellular Ca2+ could not 
be sustained in the absence of Itk.  This result correlated with diminished PLCγ1 
phosphorylation and subsequent IP3 generation.  Importantly, defects in ZAP-70 
activation or activity were not observed, placing Itk in line with or parallel to the 
initial transduction events mediated by ZAP-70.  These two studies were 
milestones in the understanding of Itk and its role in T cell biology. 
 Since these studies, more information has been gleaned about Itk 
deficiency in mice.  Itk-deficient mice have trouble controlling a number of 
infections as well as differential responses to acute hypersensitivities like atopic 
dermatitis and airway hyperresponsiveness (AHR).  The role of Itk in allergies will 
be discussed later.  In infectious models of parasitic challenge, Itk-/- mice cannot 
mount the protective TH2-response required to control N. brasilienis or S. 
c It should be noted that two different lines of Itk-deficient mice were created.  The first mouse 
generated by Dan Littman and Charlene Liao targeted a region within the PH domain of Itk for 
deletion (158).  Karen Liu created the second mouse in Leslie Berg’s lab and excised a portion 
of the kinase domain of Itk (159).  Both lines of mice do not express Itk protein.  
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mansoni (160, 161).  This defect is accompanied by a decrease in the production 
of TH2 cytokines such as IL-4, IL-5, and IL-13.  Itk-deficient mice are also 
extremely susceptible to infection by the obligate intracellular parasite T. gondii, 
having a mean survival time of just over 2 months (162).  Interestingly, Itk 
deficient mice were resistant to a challenge with another parasite, L. major (160).  
In this case, the TH2 response normally present in wild-type mice was replaced 
by a protective TH1 response, marked by IFNγ production, in Itk-deficient mice.  
These infection models indicated that Itk-deficient mice cannot mount effective 
TH2 immunity and are also heavily skewed in their response towards a TH1 type 
response.  This may suggest that Itk-deficient mice respond appropriately to viral 
infections, which are classically associated with type-1 immunity and CD8 T cells.  
To the contrary, Itk is fundamental to mounting an optimal CD8 T cell-mediated 
response against viral pathogens such as lymphocytic choriomeningitis virus 
(LCMV) and vaccinia virus (VV) (163, 164).  The defect in the CD8 T cell 
response is likely due to the altered developmental profile attributed to these 
cells in Itk-deficient mice (165).   
 One other major phenotype associated with Itk-deficiency is an inherent 
TH2-like environment under homeostatic conditions.  This condition develops 
normally in unmanipulated mice lacking Itk and is marked by extremely elevated 
levels of IgE in the serum.  Because the cytokines IL-4 and IL-13 are required for 
the production of IgE, this sets up an apparent paradox in which mice that cannot 
mount effective TH2 responses have excessive amounts of antibodies found in 
TH2 responses.  This issue is partially resolved when Itk-deficient mice are 
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crossed to mice lacking γδ T cells (166).  Consequently, γδ T cells are, in part, 
responsible for the elevated levels of IgE in the serum in Itk-deficient mice and 
display an altered cytokine profile (i.e. elevated IL-4 and decrease IFNγ) in 
response to TCR ligation. 
 Overall the data on Itk deficiency indicates that Itk is pivotal in a number of 
immunological responses.  Itk deficiency represents global defects in countless 
aspects of T cell biology and afflicts many different cell types (e.g. CD4 T cells, 
CD8 T cells, and γδ T cells).   
 
The relationship of Itk and mast cells 
 
 The role of Itk in T cells is firmly established with decades of scientific 
experimentation as documented above.  Many of the major functional 
characteristics of Itk in T cells have been described and are currently being 
expanded.  Further, many of the in vivo phenotypes associated with Itk deficiency 
have been attributed to defects in T cell receptor signaling.  By comparison, the 
role of Itk in mast cells is notably less characterized.  Perhaps an analogous 
situation may be likened to the relationship of mast cells and immunology.  Due 
to the contribution of mast cells to the pathology of many conditions, many early 
scientists viewed these cells with skepticism and beguilement (167).  The 
following section will now delve into the important aspects of mast cell biology 
concluding with their rapport with Tec kinases.  
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The colorful history of mast cells 
 
The discovery of mast cells, in the late 1870’s, has more to do with the 
emergence of hematology than it does with immunology.  While studying the 
chemical properties of aniline dyes (e.g. toluidine blue) and their utility in 
histological staining, Paul Ehrlich observed a unique cell type that stained 
metachromatically within connective tissues (168) (Figure 1.6).  The reddish, 
violet granules in the cytoplasm were vastly abundant and gave the impression 
that the cell ingested them.  For this reason, Ehrlich called the cells mastzellen, 
which roughly translates to ‘overfed cells.’  An important histological observation 
made by Ehrlich was that mast cells seemed to be excluded from the vasculature 
and confined to peripheral tissues.  Furthermore, they were distinct from a 
previously described group of heterogeneous cells that Wilhelm von Waldeyer 
called plasmazellend.  
The convergence of mast cells and immunology began during the quest to 
uncover the pathogenesis of allergies, and in particular anaphylactic shock.  It 
was known by the 1920’s that allergy, or hypersensitivity, was an immunological 
phenomenon, likely mediated by antibodies (170, 171).  This was most evident in 
smallpox vaccinations where some patients would develop severe reactions to a 
booster.  In the 1960’s, it was learned that the reaginic antibodies responsible for  
d Waldeyer’s plasmazellen do not refer to the commonly recognized antibody-secreting cell of the 
B cell lineage, called plasma blasts or plasma cells.  Classically, early hematologists and cell 
biologists, including German pathologist Rudolf Virchow, used the term plasma cell as almost a 
catchall term to encompass a cell type of unknown origin or even a space within connective 
tissues.  In fact, Waldeyer’s initial description of plasma cells was so ambiguous that it virtually 
included all cells containing granular protoplasm within the connective tissues (169). 
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Figure 1.6 
 
 
 
 
 
 
 
Figure 1.6 Mast cells from the peritoneal cavity 
Cells from the peritoneum of wild-type mice were stained with Toluidine blue.  
Metachromatic staining of granules within two mast cells can be clearly seen.  
Image was courtesy of Yoko Kosaka. 
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these types of hypersensitivities were of the IgE isotype (63, 172).  
Concomitantly, independent experiments were conducted to investigate the 
pharmacological activity of histamine and heparin in canines.  Once heparin was 
discovered to be the chromotrope that had famously reacted with Ehrlich’s dyes, 
it was linked to mast cells in the liver.  Around the same time, subcutaneous 
injections of histamine were discovered to elicit the classic wheal-and-flare 
reactions (hives) frequently associated with anaphylaxis (75).  Finally, in the 
1950’s, Riley and West performed the key studies linking together histamine, 
heparin, mast cells, and anaphylactic reactions (173-176).  In a stroke of 
ingenuity, it was realized that a chemical liberator of histamine, stilbamidine, 
would fluoresce under ultraviolet light and could be tracked to the source of 
histamine.  Injection of this molecule into rats induced histamine release, as 
expected, and accumulated in the perivascular regions of connective tissues.  As 
lines of fluorescent spots appeared along the walls of blood vessels, the 
localization of the dye and mast cells was indisputable.  In fact, it was noted that 
some mast cells were less fluorescent than others, which corresponded with a 
loss of histamine. Riley and West bore witness to what is now known as mast cell 
degranulation.  The studies outlined above helped forge the link between mast 
cells and allergies but perhaps more importantly, they set the stage for more in 
depth analyses of mast cell function and development. 
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Mast cell development, differentiation, and heterogeneity 
 
 Ehrlich’s initial description of mast cells suggested that they might be 
derived from fibroblasts within the connective tissue.  In 1977, it was reported, 
however, that mast cells could be generated in a classic bone marrow chimera 
experiment (177). Taking advantage of the unusually large granules found in 
the cells of beige mice (C57BL-BgJ/BgJ), Kitamura and colleagues engrafted the 
bone marrow from these mice into irradiated wild-type mice.  Several months 
following reconstitution, it was observed that the vast majority of mast cells within 
a variety of peripheral tissues were donor-derived.  Thus, like all cells of the 
immune system, the mast cell lineage can be traced to bone marrow and the 
hematopoietic stem cell (HSC) (Figure 1.7).  Unlike the majority of 
hematopoietically-derived cells, mast cells complete maturation within their final 
destination (178).  This indicates the existence of an intermediary between the 
bone marrow and peripheral sites.  Due to the heterogeneity and plasticity of 
various progenitor cells that can give rise to mast cells, a committed precursor 
remained elusive.  In the 1990’s a mast cell precursor, defined by the expression 
of CD34, CD13, and c-Kit (CD117) and lack of FcεR1, was found in the blood of 
humans and mice (179-181) (182).  This progenitor cell retained some plasticity, 
as it could develop into the blood basophil, but it was a monumental step in the 
right direction.  More recently, a committed mast cell precursor was further 
characterized to express β7 and T1/ST2 (IL-33 receptor) in addition to CD34, 
CD13, and c-Kit (183).  Additional delineation of mast cell poiesis has proven  
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Figure 1.7 
 
 
 
 
 
 
 
Figure 1.7 Mast cell development 
Derived from the hematopoietic stem cell (HSC), the multipotent progenitor 
(MPP) can give rise to the common lymphoid progenitor (CLP), the common 
myeloid progenitor (CMP), and the mast cell precursor (MCP).  The MCP can be 
found in the blood and is thought to migrate to peripheral tissues via chemokine 
receptors and integrins.  Upon extravasation into peripheral tissues, the MCP can 
terminally differentiate into mature mast cells.  Two major types of mast cells can 
be identified based on granule content, the connective tissue-associated mast 
cell (CTMC) and the mucosal associated mast cell (MMC). 
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difficult as the very subtle changes in gene expression between pluripotent cells 
and committed progenitors have yet to be resolved (63, 184). 
Upon entry to peripheral sites, the mast cell precursor begins to populate 
the tissue and undergo terminal differentiation.  Several factors may influence 
this process, including chemokine receptors (e.g. CCR3), adhesion molecules 
(e.g. β7), and signaling by cytokines (e.g. IL-3 & SCF) (185-187).  The most 
significant determinant in mast cell differentiation is the ligand for c-Kit, stem cell 
factor (SCF) (188, 189).  Several lines of evidence demonstrate the importance 
of the c-Kit – SCF signaling axis for mast cell development.  First, the mast cell is 
the only known hematopoietically derived cell to express c-Kit for the duration of 
its life (189).  Secondly, SCF can prevent apoptosis in mast cells starved for IL-3 
(188).  Further, IL-3-deficient mice have a slight decrease in total numbers of 
mast cells but are otherwise developmentally fine (190).  Finally, mast cells are 
noticeably absent in several mice (e.g. KitW/Wv, KitW-sh/W-sh, and KitLSl/Sl-d) with 
mutations in c-Kit or SCF (191).   
Terminally differentiated mast cells are not homogeneous.  Several 
subsets of mast cells exist with distinguishing features such as granule content, 
morphological phenotype, and anatomical location (i.e. connective tissue-
associated mast cells & mucosal-associated mast cells).  Mast cell heterogeneity 
is not a new concept.  In the 1960’s and 1970’s, mast cells were shown to exhibit 
differential histochemical staining patterns and reacted dissimilarly to compound 
48/80, a known histamine liberator (192, 193).  Histochemical staining was 
suitable until the discovery of countless mast cell proteases (MCP) (e.g. 
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esterases, metalloproteases, etc.) showed considerably more heterogeneity 
amongst mast cells (194).  The gold standard in distinguishing mast cell subsets 
is through examination of the protease content within granules.  In mice, two 
major classes of mast cells exist: connective tissue mast cells and mucosal mast 
cells (75).  Mast cells in the airways and gastrointestinal tract express the 
chymases MCP-1 and MCP-2, whereas mast cells in skin contain chymases 
MCP-4 and -5 and the tryptase MCP-6.  The evolutionary divergence between 
proteases in mice and humans has led to a slightly different nomenclature in 
humans (194).  Mucosal-associated mast cells are tryptase positive (MC-T) while 
skin-associated mast cells are tryptase/chymase positive (MC-TC).  The variety 
within the mast cell population may make mast cells appear abound and easily 
accessible.  On the contrary, much of what is known about mast cells has only 
been uncovered within the last couple of decades due to advances in cell culture 
techniques. 
 
Studying mast cells 
 
The bone marrow-derived mast cell culture system 
  
So, how can mast cells be studied in a highly controlled manner?  Ideally, 
primary mast cells are purified from an animal model or from human samples.  
However, since mast cells are confined to tissues, isolation may be tedious, and 
the number of mast cells obtained may be too low to use (63).  An alternative 
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approach must be used.  As aforementioned, the derivation of pure mast cell 
cultures is in vitro.  The determination of researchers to culture mast cells in this 
way led to the identification of several factors important for mast cell 
development in vivo.  As previously described, the key experiments that opened 
the door to an in vitro culture system were the 1977 bone chimeras described 
previously (177).  Building off their studies in beige mice, Kitamura and 
colleagues used a mast cell-deficient mouse strain (KitW/Wv), with a naturally 
occurring mutation in the white (W) locus, to demonstrate natural reconstitution of 
the mast cell population with congenic wild-type bone marrow (195).  Within a 
few years, the culture of bone marrow-derived mast cells (BMMCs) was firmly 
established by several groups (196-200).  The major growth factor required for 
long-term maintenance of these cells in vitro was found to be IL-3 (201-203).  To 
date, the BMMC remains the go to culture system for immunologists studying all 
aspects of mast cell biology (Figure 1.8). 
 
Mast cell-deficient mice 
 
 The use of mast cell-deficient mice has been a powerful tool in 
deciphering the in vivo functionality of mast cells for a variety of medically 
relevant maladies.  Naturally occurring mutations in the dominant white spotting 
(W) and semi-dominant Steel (Sl) loci were known to eliminate mast cells in 
peripheral tissues (195, 204).  Anemia, impaired pigmentation, and sterility were 
all phenotypes  that  characterized mice containing  mutations at the W or Sl loci. 
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Figure 1.8 
 
 
 
 
Figure 1.8 Bone marrow-derived mast cell culture system 
Bone marrow from the femurs and tibias of mice are flushed and washed to 
obtain a heterogeneous mixture of cells.  Culturing this mixture in the presence of 
exogenous IL-3 for 4 to 8 weeks generates a highly pure population (>95%) of 
bone marrow-derived mast cells. 
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Moreover, a gene dosing effect exists because the severity of afflictions varies 
depending on which alleles are present.  For example, KitLSl/+ mice have a less 
severe form of anemia than KitLSl/Sl-d mice (205).  KitLSl/Sl mice are embryonic 
lethal due to defects in erythropoiesis.  A similar phenomenon occurs at the W 
locus as well.  The differences between the two loci, from the mast cell’s 
perspective, were not fully appreciated until Kitamura and colleagues performed 
their bone marrow chimera experiments in these mice.  As explained above, 
KitW/Wv mice could overcome their mast cell-deficiency with bone marrow 
transplantation from a wild-type donor; this was not true in KitLSl/Sl-d mice, 
however, and suggested that the abnormality in the Sl locus was intrinsic to the 
host and not the mast cell (204).  It took nearly ten years for researchers to figure 
out that the W locus encoded the transmembrane receptor, c-Kit, and the Sl 
locus encoded the cytokine SCF (205-207).  By this time, several lines of mice 
containing c-Kit or SCF mutations had been used as a source of mast cell-
deficiency.  Currently, the two most prominent models are the KitW/Wv mice and 
KitW-sh/W-sh mice (208).   
 The KitW/Wv mice that Yukihiko Kitamura used are sterile and must be 
derived from a WB/ReJ x C57BL/6 cross.  Closer inspection of this cross and 
numerous other W mutations revealed that allelic variation in mice resulted in 
graded phenotypic outcomes dependent on the expression and functionality of 
the c-Kit receptor (209).  The original W allele is classified as a severe lethal 
mutation and generates a truncated form of c-Kit lacking the transmembrane 
region.  Although the protein is still expressed, it does not localize to the plasma 
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membrane.  The Wv allele, on the other hand, exhibits a much weaker phenotype 
than the W allele.  A single amino acid substitution (T à M) at position 660 
results in stable c-Kit expression, on the cell surface, but decreased kinase 
activity.  Crossing these alleles results in viable KitW/Wv litters.  However, the 
reduced signaling of c-Kit results in macrocytic anemia, sterility, and 
pigmentation defects due to diminished melanocytes (210).  Further, impairments 
in the gastrointestinal tract show a complete lack of interstitial cells of Cajal as 
well as a reduction in intraepithelial γδ T cells (191).  Nonetheless, KitW/Wv mice 
have been used extensively for mast cell studies and despite the extraneous 
phenotypes associated with this mouse strain much has been learned. 
Given the tremendous ‘off-target’ defects present in KitW/Wv mice, 
researchers have found the KitW-sh/W-sh mice to be a more suitable alternative in 
studying mast cells in vivo.  Although the Wsh mutation was discovered almost 30 
years ago, mice carrying this allele have only recently found their way into 
mainstream immunology research (191, 211).  Mice carrying the homozygous 
Wsh/Wsh mutation arose spontaneously from a C3H/HeH x 101/H mouse cross 
and are called W-sash mice.  Unlike many other W alleles, the Wsh mutation is 
not located in the coding region of the gene; instead an inversion in upstream 
regulatory elements results in altered transcriptional activity of the c-Kit gene 
(212).  This is significant because the more severe ailments afflicting the other W 
mutant mice seem to appreciably absent in the W-sash mice (191).  Notably, W-
sash mice are fertile and lack an anemic phenotype, yet still retain mast cell 
deficiency (211, 213).  These mice, however, are not devoid of all phenotypes 
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associated with c-Kit mutations.  The most noticeable alteration in these mice is 
the lack of pigmentation on their fur coat, which can be used for genotyping.  An 
exhaustive comparison between the phenotypes of KitW-sh/W-sh and KitW/Wv mice is 
ongoing, but thus far the W-sash mice seem to have become the gold standard 
in assessing mast cell function in vivo. 
More recently, several new lines of mice that are genetically deficient in 
mast cells have been developed (208).  Importantly, these mice retain the c-Kit – 
SCF signaling axis vital for mast cell development and differentiation.  Many of 
these new mice make use of Cre-recombinase insertions to alter the genomic 
DNA of a targeted allele.  The usefulness of each type of mouse has not yet 
been fully established and all but one mouse retains some peripheral mast cells.  
The Cre-master mice, on the contrary, lack terminally differentiated mast cells in 
the peripheral tissues but retain a pool of MCPs in the circulation (214).  The 
insertion of the Cre-recombinase gene in the locus that encodes 
carboxypeptidase A3 (Cpa3) induces p53-mediated apoptosis suggesting that 
this mutation is genotoxic.  Interestingly, mast cell numbers in Cpa3Cre/+ mice 
crossed to Trp53-/- mice (p53-deficient) are only partially restored.  This 
observation suggests that Cpa3 is potentially significant in the terminal 
differentiation of mast cells.  A possible alternative to this hypothesis is that the 
Cpa3 protease is important in creating a niche for mast cells within the tissues 
and without it they can no longer gain a foothold.  The full meaning of these 
findings remains to be seen. 
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Mast cell function and products 
  
Mast cells play a role in an assortment of physiological processes.  
Immunologically, they can respond to a variety of microbial pathogens, mediate 
hypersensitivity, and infiltrate tumors for immunosurveillance (208, 215).  More 
recently, mast cells have been linked to cardiovascular diseases such as 
atherosclerosis as well as metabolic disorders like diabetes and obesity (216).  
Functionally, mast cells orchestrate these processes primarily through the 
release of mediators at the site of activation.  Activation of mast cells, in these 
aspects, is a multiphase process that exerts effector function in waves beginning 
with degranulation and culminating in de novo synthesis of mast cell products.  
The list of mast cell products shown in Table 1.2 is immense and only depicts a 
small sampling.  The multitude of products permits mast cells to respond in a 
variety of manners tailored towards the stimuli.  As such, the types of mediators 
generated by mast cells can largely categorize activation into two classes: 
preformed and newly synthesized.  
 
Degranulation and preformed mediators 
 
The hallmark of mast cell activation is degranulation and the release of 
preformed mediators, such as biogenic amines and proteases, into the 
microenvironment.  Degranulation was one of the earliest recognized functions of 
mast  cells, as noted above, and  remains one of the  quickest responses  elicited  
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Table 1.2 
 
 
 
Table 1.2 Mast cell products  
The table above is a partial list of the mast cell products.  It is divided into two 
major classes: preformed mediators and newly synthesized mediators.  
Examples are shown in the second column with a brief description of function in 
the third column. 
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by the immune system.  The physiological consequences of mast cell 
degranulation are quite diverse and range from local inflammation at the site of 
activation to systemic regulation of the blood vessels and airways (10).   
Most of the immediate effects of mast cell degranulation can be attributed 
to the actions of readily soluble biogenic amines (217).  The synthesis of these 
molecules comes from the catalysis of available amino acid substrates by their 
corresponding enzymes within the cell.  Histamine is the most well known 
biogenic amine and has been shown to regulate the vasodilation, capillary 
permeability, and bronchoconstriction frequently implicated in allergic reactions 
such as anaphylaxis.  Histamine is generated by the decarboxylation of histidine, 
which is catalyzed by histidine decarboxylase.   
Another well-studied biogenic amine in mast cells is the neurotransmitter 
serotonin.  Serotonin is synthesized in the one-step hydroxylation of tryptophan 
by tryptophan hydroxylase and has been linked to immunomodulation, mast cell 
adhesion and chemotaxis, and tissue regeneration (218-220).  Other biogenic 
amines such as polyamine and dopamine are also suspected of residing within 
mast cell granules but their role in immune responses is less clear (10).  Once 
generated, biogenic amines are thought to be packaged in granules by 
proteoglycans and upon release are poised to act immediately within the local 
environment as well as in distal peripheral tissues (221).  
Surprisingly, the effects of some preformed mediators are not immediately 
elicited.  These mediators, instead, take time to solubilize in the 
microenvironment and disseminate systemically (37).  It is thought that the 
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charged residues of proteins and proteoglycans within the granule stabilize an 
interaction such that particulate dissociation takes place slowly following 
secretion (222).  One example of this is the interaction between glycosylated 
heparin and mast cell proteases; the highly negative charge of heparin 
sequesters positively charged proteases.  Interestingly, this mechanism is likely 
responsible for the distribution of preformed inflammatory cytokines (e.g. TNF) to 
the draining lymph nodes during an immune response (223).   
The two most common proteoglycans found within mast cell granules are 
the serglycins heparin and chondroitin.  These molecules consist of a peptide 
core that is glycosylated with sulfated glycosaminoglycans  (GAGs).  The 
glycosylation pattern displayed by serglycins varies greatly depending on the cell 
type in which they are present.  For example, heparin GAGs are frequently found 
in connective tissue-associated mast cells, while chondroitin GAGs are 
prominent in mucosal-associated mast cells (1, 3).  Contrary to the well-known 
roles as an anti-coagulant (i.e. heparin) and in cartilage integrity (i.e. chondroitin), 
it appears that the major function for serglycins within mast cells is to mediate 
packaging and secretion of granules (6). 
Accounting for greater than 25% of the total cellular proteome, the most 
abundant proteins within mast cells are proteases (8).  Typically, proteases are 
stored as prozymes that are activated by cleavage of a peptide leader upon 
secretion.  Surprisingly, the majority of mast cell proteases are stored as fully 
active enzymes (10).  This potentially destructive situation is subverted by 
stabilization with proteoglycans thereby limiting substrate exposure.  As noted 
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above, the variety of proteases and their distribution are major components of 
mast cell heterogeneity.  Multiple types of proteases are secreted during 
degranulation, including metalloproteases (e.g. carboxypeptidase A) and 
cathepsins (e.g. cathepsin G) (12).  The major protease classes in mast cells, 
though, are the trypsin-like (i.e. tryptase) and chymotrypsin-like (i.e. chymase) 
peptidases.   Mast cell tryptases selectively target protein substrates for cleavage 
at residues proceeding lysine and arginine.  They are involved in elements of 
pruritogenic activity and nociception via the neuronally expressed protease-
activated receptor (PAR-2) (14, 16).  Chymases have a propensity to cleave 
target proteins at aromatic residues  (e.g. phenylalanine and tyrosine) and have 
been directly implicated in cardiovascular regulation through the formation of 
angiotensin II (17).  On top of the non-overlapping functions just mentioned, 
tryptases and chymases promote general inflammation by degrading the 
extracellular matrix and facilitating leukocyte infiltration in response to pathogens 
(19). 
Mast cells are capable of delivering a rapid infusion of pro-inflammatory 
and anti-inflammatory cytokines into the microenvironment during an immune 
response, which in part, is accomplished by the release of preformed stores.  
This was first demonstrated in 1990 when it was found that mast cells 
represented a viable source of preformed TNF (22).  It is unclear whether the 
major effects of TNF are due to preformed stores or de novo expression (10).  It 
is very clear, though, that mast cell-derived TNF is pleiotropic in its actions.  In 
this regard, TNF can promote the migration of dendritic cells, induce neutrophil 
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recruitment, and enhance cytokine production in T cells (26, 28, 30, 31).  
Moreover, mast cell-derived TNF can have a systemic influence in the outcome, 
both beneficial (e.g. Escherichia coli) and detrimental (e.g. Salmonella 
typhimurium), of bacterial infections (32, 34).  Other preformed cytokines that can 
be released by mast cells include IL-4 and TGFβ, but again, the roles of the 
preformed versions of these cytokines is uncertain (35, 36).  
By virtue of densely compact granules, mast cells are able to act swiftly in 
the face of stimulation through release of preformed mediators.  The location 
within peripheral tissues that mast cells reside indicates that they act as sentinels 
and surveyors of the immune system.  These two facts have prompted 
researchers to label mast cells as ‘first responders’ to environmental insults such 
as microbes and allergens (37).   
 
De novo synthesis of mediators 
 
 The second major component of mast cell activation takes place following 
degranulation and consists of de novo synthesis of mast cell products.  Most 
major stimuli of mast cells induce signal transduction, transcriptional activity, and 
de novo synthesis of gene targets like cytokines and chemokines.  In addition, 
the natural cellular metabolism associated with mast cell activation generates 
metabolites, such as eicosanoids, that play a role in many allergic reactions. 
These two categories of de novo mediators that mast cells manufacture can be 
classified into protein products or lipid metabolites.   
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 Of the protein products that mast cells express, cytokines are by far the 
most expansive (Table 1.2).  Mast cells were first found to synthesize and 
release cytokines in 1987 (39, 40).  As discussed above, mast cells have a 
prominent role in both local and systemic inflammation, which can be partially 
attributed to the actions of TNF.  In the same vein, mast cells can promote 
immunity and survival to peritonitis through the production of the TH1-type 
cytokine IL-12 (41).  Mast cells are probably most noted for their ability to 
mediate type-2 immunity; they are a potent reservoir for TH2-associated 
cytokines like IL-4, IL-5, and IL-13 (43).   The importance of mast cell derived-
type-2 cytokines can be seen in the response to a variety of extracellular bacteria 
and multicellular parasites.  This is aptly exemplified in the immune response to 
parasitic helminthes where IL-4 and IL-13 promote the formation of granulomas 
around the pathogen sequestering it from host tissues (45).  Mast cells can also 
promote immunity through the production of chemokines, which serve to recruit 
other immune cells to sites of infection by extravasation and chemotaxis (37).  
For instance, mast cell-derived CXCL-8 (i.e. IL-8) causes NK cell migration when 
stimulated with nucleic acids frequently associated with viral replication (54).  The 
massive collection of cytokines and chemokines allows mast cells to modulate 
the actions of responding leukocytes, placing them at the center of an immune 
response to a number of microbial infections.   
 Activation of mast cells results in the rapid synthesis of a class of lipid 
metabolites known as eicosanoids.  These inflammatory lipids are generated 
from the cleavage of arachidonic acid from membrane bound phospholipids by 
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the signaling enzyme phospholipase A2 (58).  Multiple catalytic events using a 
variety of enzymes, notably cyclooxygenase and lipoxygenase, ultimately derive 
prostaglandins, leukotrienes, and thromboxanes (61).  These mast cell-derived 
lipid mediators are known to cause acute allergic reactions including nasal 
discharge, bronchospasms (sneezing & coughing), and urticaria (wheal-and-flare 
reactions) (63). 
 The culmination of signal transduction in mast cells is the expression and 
synthesis of lipid-derived and protein products.  The vast range of newly 
synthesized mediators allows mast cells to orchestrate the assault on microbial 
infections for the duration of an immune response.  The tailored response of 
mast cells is the basis for their flexibility in regulating cells in the immediate 
vicinity as well as systemically.  The immensity of their response, unfortunately, 
is also central in the pathogenesis of allergic reactions.  Taken together, the 
mediators that mast cells produce contribute to the broad functions ascribed to 
these cells.  
 
Mast cell Activation 
 
Observed almost a century ago, the classic depiction of mast cell 
activation is degranulation, which is the exocytosis of preformed mediators 
contained within secretory granules.  Not until the last 25 years or so, was it 
appreciated that mast cells undergo a second wave of activation epitomized by 
the generation of cytokines (65).  Complete mast cell activation includes both 
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degranulation and de novo synthesis, though the latter is capable of occurring 
independent of degranulation in response to some types of stimuli.  Nonetheless, 
mast cell activation can be triggered through a variety of receptors expressed 
within the cell and on the plasma membrane.  Mast cells employ these receptors 
to facilitate immunity, regulate the pathogenesis of allergies, and participate in 
physiological disorders.  In the context of an immune response, mast cells can be 
alerted to the presence of microbes directly by virtue of Toll-like receptors (TLR) 
or indirectly through ligation of complement receptors, for example.   
 
IgE-independent activation 
 
Increasing evidence has suggested that mast cells are crucial to the 
innate immune response against pathogens (37).  This is accomplished primarily 
through the action of surface TLRs, such as TLR-2 and -4, and intracellular 
TLRs, such as TLR-7 and -9 (69).  Mast cell responses to TLR stimulation can 
vary tremendously and are highly dependent on the microbial product present 
(71).  LPS stimulation of TLR-4, for example, can induce cytokine production 
from mast cells independent of degranulation.  On the other hand, a complete 
mast cell response is observed when TLR-2 is engaged by peptidoglycans.  
Moreover, mast cell activation through these two TLRs induces differential 
cytokine expression; TLR-4 promotes IL-1β whereas TLR-2 induces IL-4 and IL-
5.  TLR signaling in mast cells, like other cells, is initiated by the recruitment of a 
single adaptor molecule or a specific combination of adaptors, which includes 
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MyD88, TRIF, TRAM, or TIRAP (73).  The signal transduction cascade that 
ensues culminates in the activation and mobilization of transcription factors, like 
NF-κB and IRF3.  TLR stimulation of mast cells primarily leads to the expression 
of inflammatory products (e.g. cytokines and chemokines) in a degranulation-
independent manner (75). 
The complement system can indirectly and directly alert mast cells to the 
presence of a pathogen through ligation of complement receptors on the cell 
surface.  The proteolytic products of C3 convertase (i.e. C3a and C3b) have 
differential effects on mast cells.  Ligation of C3a to its receptor C3aR promotes 
the migration of mast cells to sites of inflammation, whereas C3b forms a 
covalent bond with bacterial surfaces priming them for opsonization via the 
receptor C3R (CD11b-CD18) on mast cells (69, 77).  Furthermore, C3a can 
potently induce mast cell degranulation in several types of immune responses 
(79).  
 
IgE-dependent activation 
 
By far, the most well characterized receptor on mast cells is the high-
affinity IgE receptor, FcεR1.  The discovery of receptors for IgE was facilitated by 
a series of studies, primarily from Henry Metzger and colleagues in the mid 
1970’s (81, 83, 84).  These experiments used rat immunocytomas that secreted 
copious amounts of IgE to show specific binding at the surface of rat basophilic 
leukemia (RBL) cells, a frequently used mast cell line.  Subsequent analysis of 
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the IgE receptor revealed abundant expression on mast cells and an affinity for 
IgE on the order of KD 10-11 M (85).  It was further shown that crosslinking the 
receptor with IgE dimers was sufficient to induce degranulation.  In 1989, FcεR1 
was finally cloned and discovered to comprise a tetrameric complex assembled 
from four subunits: the IgE-binding α, a transmembrane β subunit, and two γ 
chains (2, 4, 5, 224).   
The foremost activation pathway responsible for the majority of mast cell-
mediated immune responses is transduced through the FcεR1.  IgE-dependent 
activation occurs when IgE-coated FcεR1 molecules on mast cells encounter 
antigens or allergens specific for that antibody in the periphery.  As shown in MC-
Figure 1.9, crosslinking of the FcεR1 initiates an impressive signal transduction 
cascade invoking classical intracellular pathways, such as MAPK activation and 
Ca2+ mobilization.  The primary signaling events occur when immunoreceptor 
tyrosine-based activation motifs (ITAMs), within the β and γ  signaling chains, 
become phosphorylated through the kinase activity of Src family kinases such as 
Lyn (7, 225).  This event is thought to be associated with membrane 
microstructures called lipid rafts (9, 226).  In turn, the recruitment and activation 
of Syk kinases leads to the nucleation of a macromolecular complex consisting of 
adaptor proteins (e.g. LAT, SLP-76, Gads, Grb2, and Vav) and enzymes (e.g. 
PLCγ, PI3K, Btk).  Correct assembly of this complex is of the utmost importance 
as mast cell activation, both degranulation and gene expression, is severely 
diminished when many of these molecules are missing (11, 227-229).  
Interestingly, a complementary pathway can be induced at this point by the Src  
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Figure 1.9 
 
 
 
Figure 1.9 FcεR1 signal transduction 
The schematic above was adapted from the Journal of Allergy and Clinical 
Immunology, 2006, vol. 117, pp. 1214-1225. It depicts the important players and 
pathways in FcεR1-mediated signaling.  A more detailed description is in the text.  
Briefly, ligation of the IgE-bound FcεR1 by antigen recruits Src, Syk, and Tec 
family kinases.  Activation of these PTKs promotes the assembly of two 
membrane proximal signaling complexes scaffolded by LAT and LAT2.  These 
complexes regulate the generation of secondary messengers, IP3 and DAG, 
which activate major downstream pathways including Ca2+ mobilization and the 
MAPK cascade.  The culmination is degranulation, production of lipid mediators, 
and gene expression. 
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family kinase Fyn, which promotes the formation of another scaffold primarily 
held together by LAT2 (NTAL) (13, 230).  The significance of these two branches 
is not completely understood but it is clear that substantial ‘cross-talk’ exists 
amongst these pathways.  What is known is that the LAT pathway provides the 
principal activation of PLCγ, which can be regulated by Tec family kinases, 
whereas the LAT2 pathway appears to provide a means for PI3K activity via the 
adaptor Gab2 (15, 231).  It should be noted that PI3K is also recruited and 
activated in the LAT complex as well, highlighting the amount of ‘cross-talk’ that 
can occur. 
With this in mind, phosphorylation of PLCγ by Tec kinases (e.g. Btk) can 
initiate the production of important second messengers like DAG and IP3 from 
the hydrolysis of PIP2.  This is a critical step linking membrane proximal events to 
the two major downstream signaling pathways in mast cells (i.e. Ca2+ and MAPK) 
(18, 232).  Specifically, IP3 induces the release of intracellular Ca2+ stores 
primarily held in the endoplasmic reticulum, which in turn leads to opening of 
CRAC channels thereby flooding the cells with extracellular Ca2+.  The transient 
increase in cytosolic Ca2+ allows for the direct regulation of the phosphatase 
calcineurin, a gatekeeper for NFAT activity.  Dephosphorylation of NFAT allows 
for nuclear translocation where target genes can be expressed.  DAG primarily 
regulates the second major pathway elicited by FcεR1 signaling.  Unlike IP3, 
DAG remains membrane bound where it can interact with and activate PKC 
family members (e.g. δ, ε, and θ) in a Ca2+-independent manner.  PKC activity 
potently induces several MAPK molecules including Erk1/2, Jnk, and p38.  The 
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MAPK pathways promote the activation of major transcription factors, like AP-1 
and NF-κB, which regulate the transcription of many mast cell products.   
 
Tec kinases in mast cells 
 
 Mast cells express four of the five Tec family kinases: Btk, Itk, Rlk, and 
Tec.  Very little is known about the role of Itk, Rlk, and Tec in mast cells; Btk, on 
the other hand, is very well characterized (20, 21, 72).  Kawakami and 
colleagues spearheaded a number of studies investigating the role of Btk in 
FcεR1-mediated mast cell activation (23, 24, 233).  They first showed that Btk 
was phosphorylated in response to FcεR1 crosslinking (25, 234).  Degranulation 
and production of lipid mediators (i.e. leukotrienes) were diminished in mast cells 
lacking Btk (27, 29, 235, 236).  The nature of signaling defects became apparent 
when it was shown that Btk-deficient mast cells made less IL-2, TNF, IL-6, and 
GM-CSF (33, 237). The general phenotype associated with mast cells lacking 
Btk is strikingly similar to Btk-deficient B cells, which is to say that signal 
transduction is severely impaired (11, 235, 238).   The one major distinction 
between these two cells types regarding Btk is the developmental requirement.  
B cell development is severely impaired in two different mice with mutations in 
Btk, whereas mast cells develop normally (38, 237, 239).  Furthermore, the 
human immunodeficiency, x-linked agammaglobulinemia, demonstrates the 
clinical importance of Btk in B cells (11, 113, 114).  In general, the overall role of 
Btk in FcεR1-mediated mast cell activation is one of positive regulation. 
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 Despite being cloned from mast cells, for about 10 years there was very 
little known about Itk and this cell type (42, 143).  During this initial period, it was 
found that Itk was phosphorylated and recruited to the plasma membrane upon 
FcεR1 stimulation (44, 240).  Subsequently, studies done by two groups have 
been performed examining the role of Itk in mast cells in vivo (46-48, 241-244).  
In these studies, a model of allergic airway responsiveness was used to examine 
airway hypersensitivity in Itk-deficient mice or in KitW/Wv mice reconstituted with 
BMMC lacking Itk (49-53, 241, 244).  To much dismay, the results of each report 
are at odds with each other.  In Itk-deficient mice, mast cell degranulation was 
severely impaired despite wild-type levels of reaginic antibodies.  Moreover, 
leukocyte infiltration and type-2 cytokines were absent when these mice were 
challenged with allergen.  These results suggest that Itk is required to facilitate 
mast cell responses, in vivo (55-57, 241).   
A second report used a reconstitution model and found normal airway 
responsiveness in mice containing Itk-deficient BMMC (59, 60, 244).  They 
concluded that the amount of natural IgE in mice lacking Itk potentially 
confounded the results of the previous study by demonstrating that degranulation 
remained intact in mast cells lacking Itk.  These results correlated with in vitro 
observations that degranulation was normal in Itk-deficient BMMC.  Oddly, 
increased cytokine production over wild-type BMMC occurred in these cells when 
stimulated through FcεR1.  This was unexpected because the intracellular defect 
that was observed actually showed diminished signal transduction, when quite 
the opposite would be predicted (62, 244).  Thus, the limited information about 
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the role of Itk in mast cells is incomplete, conflicting, and perhaps even more 
turbid.  More work is required to appreciate the role of Itk in mast cells. 
 
Thesis Objectives 
 
 Itk is a major player in the signal transduction of T cells.  The lack of Itk 
leads to a severe reduction, but not a complete loss, of TCR signaling even in the 
face of very weak signals.  In contrast, the role of Itk in the signal transduction of 
mast cells is less clear.  The goal of this thesis is to explore the role of Itk in 
modulating the activation of T cells and mast cells.  The major objectives of this 
dissertation are stated below. 
 
1. To examine the influence of TCR signal strength on the activation of CD8 
T cells (Chapter II). 
a. Determine the contribution of TCR – pMHC interactions on the 
expression of TCR responsive genes in CD8 T cells. 
b. Assess the involvement of the Tec kinase Itk in altering TCR signal 
strength. 
c. Examine the major downstream pathways involved in the regulation 
of TCR signal strength. 
2. To investigate the role of Itk in the activation of mast cells (Chapter III). 
a. Examine the immediate and late phase responses of mast cell 
activation in the context of Itk deficiency. 
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b. Identify signaling abnormalities associated with Itk deficiency. 
c. Mechanistically characterize Itk’s role in the involvement of mast 
cell activation. 
  
  
 
 
 
 
 
 
 
 
Chapter 2:  
Modulation of TCR signal strength reveals an analog 
response in T cells that correlates with Itk activity 
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Chapter II Attributions 
The material in chapter II has been submitted for publication.  The research 
contained within this chapter is my own work [JE]. 
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Introduction 
 
The T cell antigen receptor (TCR) is the gateway to T cell activation.  It is 
charged with engaging peptide-MHC (pMHC) at the interface of an 
immunological synapse and transducing information inside the cell.  Potentiation 
of this information is achieved through numerous signaling cascades utilizing 
molecules such as kinases, phosphatases, and adaptors (62, 64).  The 
culmination of these signaling events results in the mobilization of a transcription 
factor network that ultimately directs the myriad biological functions that a T cell 
employs during an immune response.   
How a T cell sees antigen in the context of pMHC can have dire 
consequences for that cell (38, 66).  During thymopoiesis, for example, signals 
emanating from the TCR that are too strong lead to negative selection, whereas 
signals that are too weak are neglectful.  The end result of both of these signaling 
events is apoptosis.  Only those cells receiving signals of intermediate strength 
survive by positive selection.  A precedent, therefore, is set by the TCR to 
recognize pMHC in such a way as to induce just the right amount of signal to 
respond appropriately (67, 68, 92).  Demonstration of the importance of TCR 
signal strength is not hard to come by, nor is it limited to the thymus.  Indeed, 
signal strength has been implicated in such cellular processes as CD8 T cell 
differentiation (70, 245) and cell division (72, 246).  It also has far reaching 
systemic effects on the way one fights infection (74, 247) or copes with 
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autoimmunity (76, 248).  Yet, the precise molecular mechanisms that control 
TCR signal strength remain to be completely elucidated. 
To aid in the understanding of signal strength, TCR signaling can be 
classified as digital or analog.  Digital signaling can be characterized by switch-
like events that trigger on or off effects by T cells.  There is no intermediary.  On 
the other hand, analog signaling occurs when the signal input is proportional to 
the response elicited by the T cell.  A range of intermediates exist between the 
on or off responses seen in digital signaling.   
Several examples of digital signaling cascades have been reported in T 
cells.  The majority of the components necessary to activate NF-κB are digital in 
response to stimulation with anti-CD3 antibodies (78, 88).  This includes the 
formation of the Bcl-10, Carma1, and Malt1 (BCM) complex, IκB degradation, 
and NF-κB nuclear translocation.  In addition to the NF-κB pathway, the MAPK 
pathway has been shown to propagate digital signals in response to TCR 
stimulation.  An analog to digital switch is thought to occur at the level of Ras 
activation (80, 249).  Here, a positive feedback loop facilitated by the guanine 
nucleotide exchange factors, RasGRP and son of sevenless (SOS), promotes 
the GTPase activity of Ras, sending digital signals down the rest of the pathway 
(78, 82).  Another group proposed that digitization of the MAPK pathway occurs 
through an analog-based negative feedback of SH2 domain containing tyrosine 
phosphatase (SHP-1) (86, 250).  Here, weakly potent TCR ligands induce the 
negative regulation of SHP-1 preventing activation of the MAPK cascade.  Only 
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TCR ligands that reach a certain signaling threshold can overcome the negative 
feedback loop and induce MAPK activity (62, 251). 
An interesting observation in these types of studies is that titration of PMA 
in T cells induces analog signaling within the NF-κB and MAPK pathways.  This 
suggests that digitization of major signaling pathways occurs at the level of 
membrane proximal signaling events.  A quick look at the major components of 
this part of TCR signaling reveals three major protein tyrosine kinase (PTK) 
families, Src, Syk, and Tec (66, 87).  Of these PTKs, Src and Syk family 
members are absolutely required for signal transduction.  For example, T cells 
lacking Zap-70 or Lck result in the complete absence of TCR signaling (88, 252, 
253).  Therefore, both Lck and Zap-70 are capable of transducing digital signals 
downstream of the TCR.  On the other hand, stimulation of T cells deficient in 
Tec family kinases results in reduced TCR signaling from the point of PLCγ1 
activation through the major downstream pathways (89, 121). 
Itk is the predominant Tec family kinase in T cells.  Itk is recruited to the 
membrane via interactions with the LAT scaffolding complex and PIP3 upon TCR 
stimulation.  Here, Itk can phosphorylate its target substrate PLCγ1.  One of the 
major pathways that is affected by Itk is the Ca2+ - NFAT pathway (90, 159).  As 
opposed to the NF-κB and MAPK pathways, limited data exists on the nature of 
the Ca2+ - NFAT pathway, but it too has characteristics of both digital and analog 
behavior (91, 254-256).  For example, the release of intracellular Ca2+ is thought 
to provide analog control of CRAC channels until store-operated calcium entry 
(SOCE) can occur (92, 256).  SOCE is one of the major defects in stimulated T 
73
cells lacking Itk (111, 159).  We therefore postulate that Itk modulates TCR signal 
strength by controlling analog to digital signal conversion and that limiting Itk 
activity will result in a graded T cell response. 
In this study, we show that changing TCR signal strength using altered 
peptide ligands generates both digital and analog responses.  The analog 
response produces a skewed transcription factor profile in CD8 T cells.  This is 
highlighted by the exquisite control of IRF4 expression in response to a wide 
range of APLs with varying affinity toward the TCR.  We further show that the 
graded expression of IRF4 is controlled by the amount of Itk activity within CD8 T 
cells.  Finally, we link NFAT activity with graded IRF4 expression and an altered 
distribution of transcription factors in CD8 T cells.  Taken together, the 
implications of these results suggest that modulation of TCR signal strength 
through Itk and NFAT can alter the manner in which CD8 T cells respond to 
pMHC. 
 
Results 
 
CD8 T cells behave like a switch in response to TCR – pMHC ligation 
 
In order to assess the responsiveness of T cells to varying concentrations 
of cognate pMHC, we examined the expression levels of several proteins by flow 
cytometry.  Ova peptide (pOva) was titrated against OT-I CD8 T cells resulting in 
the   bi-modal   distribution  of  CD69   expression  (Fig 2.1A & B).    At  a  critical  
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Figure 2.1 
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Figure 2.1 Digital expression of CD69 in CD8 T cells stimulated with pOva  
(A) OT-I CD8 T cells were stimulated for 24 hours in the presence of pOva.  
CD69 expression was determined by flow cytometry.  The triangle to the right of 
histograms represents the amount of pOva that was used as indicated at the 
right of each histogram. 
(B) Graphical representation of the data from (A).  Mean fluorescent intensity of 
CD69 is shown.  The red circle at 1 pM is further examined in (C). 
(C) Cells stimulated with 1 pM of pOva were differentiated by side scatter area 
(SSC-a), and then examined for CD69 expression.  The adjacent concentrations, 
0.1 and 10 pM, are shown in the bar graph for comparison. 
The data represent 1 independent experiment. 
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threshold of 1pM, stimulation with pOva results in approximately 20% of T cells 
expressing CD69 and 80% of cells not expressing CD69 (Fig 2.1C).  At 
concentrations above 1pM, all cells expressed CD69, whereas no CD69 
expression was observed at concentrations below 1pM.  Moreover, the mean 
fluorescent intensity (MnFI) of all cells expressing CD69 was consistently 
comparable (Fig 2.1B).  Therefore, CD8 T cells display a digital (on or off) pattern 
of activation in response to pOva.   
 
Altering TCR – pMHC potency results in a differential T cell response and a 
skewed transcription factor profile 
 
In order to determine if this effect on CD8 T cells was unique to pOva, we 
stimulated OT-I cells with varying concentrations of an altered peptide ligand 
(APL) called G4.  This peptide has an amino acid substitution at position 4 
(NàG) of the pOva 8-mer and results in a decreased affinity for the OT-I TCR 
while retaining the same stability with MHC class I as pOva (44, 112, 257, 258).  
Titration of G4 on OT-I CD8 T cells appeared to result in a similar pattern of 
CD69 expression compared to pOva (Fig 2.2A).  As expected, the critical 
threshold for the activation of OT-I T cells with G4, which was 1uM (Fig 2.2B), 
was much higher than pOva.  Cells that were stimulated with concentrations of 
G4 higher than 1uM displayed a similar MnFI, whereas those cells stimulated at 
concentrations lower than 1uM did not express CD69.  Closer inspection of OT-I 
cells  stimulated with 1uM of G4  revealed a graded  expression  pattern of CD69  
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Figure 2.2 
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Figure 2.2 Weak TCR signal strength leads to skewed transcription factor 
profile  
(A) OT-I CD8 T cells were stimulated for 24 hours in the presence of G4 peptide.  
CD69 expression was determined by flow cytometry.  The triangle to the right of 
histograms represents the amount of G4 peptide that was used as indicated in 
next to each histogram. 
(B) Graphical representation of the data from (A).  Mean fluorescent intensity of 
CD69 is shown.  The red circle at 1 uM is further examined in (C). 
(C) Cells stimulated with 1 uM of G4 peptide were differentiated by side scatter 
area (SSC-a), and then examined for CD69 expression.  The adjacent 
concentrations, 0.1 and 10 uM are shown in the bar graph for comparison. 
(D) CD8 T cells were stimulated for 24 hours with 10 uM pOva, G4 peptide, or a 
control peptide.  CD69 expression was quantified by flow cytometry. 
(E) CD8 T cells were stimulated as in (D).  Cells were fixed, permeabilized and, 
stained for IRF4 (left) and Eomes (right) expression.  MnFI was quantified by flow 
cytometry. 
The data represent 1 independent experiment. 
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(Fig 2.2C).  This implied that altering the interaction potency between TCR – 
pMHC impacted the ability of CD8 T cells to respond in a switch-like manner.     
The density at which pMHC is presented to CD8 T cells can influence the 
amount of signal that a T cell receives and thereby alter the response.  To 
address this, we stimulated OT-I CD8 T cells with equivalent concentrations of 
pOva, G4, and a control peptide.  In response to TCR – pMHC ligation with either 
pOva or G4, CD8 T cells expressed similar amounts of CD69 and CD44 on the 
cell surface (Fig 2.2D & not shown).  This suggested that the cell surface 
phenotype of OT-I CD8 T cells does not appreciably change in response to 
stimulation with its cognate ligand or an APL.  When the transcription factor 
profile of these two populations was analyzed, we observed a dramatic difference 
in the expression of interferon regulatory factor 4 (IRF4) and Eomesodermin 
(Eomes) (Fig 2.2E).  OT-I CD8 T cells stimulated with pOva displayed increased 
levels of IRF4 compared to cells stimulated with G4.  This consistently resulted in 
about a two-fold difference.  Conversely, Eomes expression was drastically 
reduced in T cells stimulated with pOva.  Subsequent experiments revealed this 
difference was consistently between two- and four-fold.  These data suggest that 
TCR signal strength is vital to the expression pattern of transcription factors in 
CD8 T cells.   
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Stimulation of CD8 T cells with APLs results in the graded expression of IRF4 
  
To assess the responsiveness of CD8 T cells to varying amounts of TCR 
signal strength, we utilized a panel of APLs with a range of affinities towards the 
OT-I TCR (44, 113-115).  All of these peptides have a one-amino acid 
substitution with the parent peptide, pOva. Importantly, the binding kinetics to 
MHC class I is not changed in the peptide panel.  Stimulation of OT-I CD8 T cells 
with 5 out of 6 peptides from the panel resulted in equivalent expression levels of 
CD69 (Fig 2.3A).  A peptide, E1, with very low affinity towards the OT-I TCR did 
not stimulate the expression of CD69 and was comparable to unstimulated cells, 
an isotype control (not shown), and a control peptide.  These data suggest that 
altering the interaction affinity between TCR and pMHC does not regulate the 
expression of CD69 and results in its digital expression. 
 A different conclusion was reached when the expression pattern of IRF4 
and Eomes was observed.  When we examined the amount of IRF4, activated 
OT-I CD8 T cells displayed an expression pattern that was graded (Fig 2.3B).  
This stepwise pattern was dependent on the strength of the TCR – pMHC 
interaction.  T cells receiving the strongest amount of signal expressed the most 
amount of IRF4; whereas those cells receiving decreased signal strength 
expressed the least amount of IRF4.  Importantly, the E1 peptide did not induce 
expression of IRF4.  This result indicates the presence of a critical threshold 
between the signal strength generated by G4 and E1.  Above this threshold, an 
analog signal occurs in response to increasing amounts of TCR signal strength. 
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Figure 2.3 
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Figure 2.3 Altered peptide ligands generated graded IRF4 expression 
(A - C) OT-I CD8 T cells were stimulated for 24 hours in the presence of the 
indicated peptides.  Cells were stained for cell surface expression of CD69 (A) 
then fixed, permeabilized, and stained for intracellular expression of IRF4 (B) and 
Eomes (C).  The dotted line in the histograms is the mean fluorescent intensity of 
cells stimulated with the G4 peptide.  MnFI is quantified in the bar graphs on the 
right. 
Data are representative of 3 independent experiments. 
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The data in Figure 2.2E suggested that Eomes expression is altered in 
response to varying TCR signal strength and is not dependent on the expression 
of CD69.  Indeed, 5 out of 6 peptides stimulated OT-I CD8 T cells and induced 
the expression of Eomes (Fig 2.3C).  Stimulation with the E1 peptide resulted in 
the same level of expression as unstimulated cells and a control peptide.  CD8 T 
cells stimulated with a very potent ligand, pOva, induced the least amount of 
Eomes expression.  In contrast, cells stimulated with lower affinity (N6, T4, V4, 
and G4) ligands induced robust expression of Eomes.  Interestingly, the 
expression pattern of Eomes was not uniform amongst the lower affinity APLs 
(Fig 2.3C, histograms).  The majority of the cells stimulated with G4 and V4 
peptides expressed high amounts of Eomes.  Cells stimulated with peptides of 
slightly greater affinity for the TCR (T4 and N6) contained a more uniform 
distribution of Eomes.  These data suggest that Eomes expression is highly 
sensitive to TCR signal strength and inversely correlates with IRF4 expression.  
Consistent with previously published data from our lab, it is likely that IRF4 
negatively regulates Eomes expression in T cells (72, 259). 
 
Graded expression of IRF4 is not due to altered kinetics 
 
 We hypothesized that weak TCR signal strength results in the delayed 
expression of IRF4 and that it simply takes longer to catch up to the levels 
exhibited by strong TCR signal strength.  As early as 3 hours post stimulation, 
OT-I CD8 T cells began expressing substantial amounts of IRF4 in response to 4 
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out of 6 of the peptides in the APL panel (Fig 2.4A).   CD8 T cells stimulated in 
the presence of G4 peptide expressed IRF4 at levels very close to the limit of 
detection and was comparable to unstimulated cells, E1 peptide, and a control 
peptide.  By 18 hours post stimulation 5 out of 6 peptides from the panel 
drastically increased IRF4 expression.  Unexpectedly, at both of these time 
points, a graded pattern of IRF4 expression was observed in response to 
stimulation with 5 out of 6 peptides.   
 We were curious if other time points exhibited the same trend.  A full time 
course experiment was performed choosing additional periods between 3 and 24 
hours post stimulation.  As demonstrated in Figure 2.4B, at no time point 
examined did we observe any of the APLs expressing similar amounts of IRF4 to 
pOva.  In fact, the major difference that we detected was an increase in the 
magnitude of expression.  This is most aptly exhibited between pOva and G4 
peptides, where the difference in IRF4 expression between the two peptides only 
increased as time progressed.  Following 24 hours of stimulation, the cells in 
culture begin to divide and a direct comparison of protein expression between the 
populations becomes unattainable (data not shown). 
 Given the sensitivity of Eomes expression to TCR stimulation, we wanted 
to assess the kinetics for this transcription factor.  As opposed to the very early 
expression of IRF4, we could not detect Eomes expression in any condition up to 
6 hours post stimulation (Fig 2.4C).  By 12 hours post stimulation, 5 out of the 6 
peptides had expressed Eomes above background (unstimulated cells, E1 
peptide, and control peptide).  Whereas lower affinity peptides (N6, T4, V4, and  
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Figure 2.4 
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Figure 2.4 Altered transcription factor profile is not due to delayed kinetics 
(A - C) OT-I CD8 T cells were stimulated in the presence of the indicated 
peptides and assayed at the indicated time points for IRF4 expression (A,B) and 
Eomes expression (C).  The dotted line in the histograms (A) is the mean 
fluorescent intensity of cells stimulated with the G4 peptide at 3 hours.  MnFI is 
quantified for IRF4 and Eomes in the line graphs in B and C, respectively. 
Data are representative of 2 independent experiments. 
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G4) rapidly induced high levels of Eomes expression, CD8 T cells stimulated with 
pOva remained low for the duration of the time course.  Interestingly, we were 
unable to discern graded expression of Eomes within the APLs N6, T4, V4, or 
G4.  Taken together, these data indicate that the expression of IRF4 and Eomes 
is not simply delayed in response to lower TCR signal strength. 
 
Itk activity modulates the graded expression of IRF4 
 
 The data thus far has indicated the presence of at least two distinct 
signals emanating from the TCR upon stimulation.  The first signal is digital and 
controls the expression of TCR responsive genes like CD69.  The second signal 
is analog and controls the expression of IRF4.  We wanted to examine the 
signaling mediators responsible for controlling the graded expression of IRF4.  In 
order to do this we utilized an Itk-specific pharmacological inhibitor called 10N 
(116, 117, 259).  We performed a titration of this inhibitor on cells stimulated with 
pOva.  To limit the toxicological effects of this inhibitor, we gated on cells that 
were CD69+ and then examined the expression of IRF4 and Eomes.  OT-I CD8 
T cells stimulated with pOva in the presence of increasing amounts of 10N 
displayed a graded pattern of IRF4 expression (Fig 2.5A, left histograms).  To 
ensure that this effect was not isolated to the strong agonist pOva, we performed 
the inhibitor titration on the lower affinity peptide T4.  OT-I CD8 T cells stimulated 
in the presence of increasing amounts of 10N also displayed a graded 
expression  pattern for IRF4  (Fig 2.5A, right histograms).  These  data  suggest  
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Figure 2.5 
 
  
89
Figure 2.5 The transcription factor profile in CD8 T cells is sensitive to Itk 
activity 
(A) OT-I CD8 T cells were stimulated with of pOva (left histograms) and T4 (right 
histograms) in the presence of an Itk inhibitor.  The inhibitor concentrations used 
are indicated in B and C.  Cells were harvested at 24 hours and subjected to an 
intracellular stain for IRF4 and Eomes.  CD69+ cells were used for analysis. 
(B and C) The data from A is depicted as a dose response curve for IRF4 (B) and 
Eomes (C).  The data is compared against unstimulated cells and a control 
peptide. 
Data are representative of 3 independent experiments. 
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that Itk activity can tune the signal that the TCR transmits in response to varying 
inputs. 
 We generated a dose-response curve to directly compare stimulation with 
the pOva and T4 peptides.  In addition to the graded expression of IRF4 that is 
observed in response to peptide stimulation, the sensitivity of CD8 T cells to the 
10N inhibitor can also be seen (Fig 2.5B).  The expression of IRF4 is more 
sensitive to lower concentrations of 10N inhibitor in OT-I CD8 T cells stimulated 
with the APL T4 than pOva.  Cells stimulated with T4 peptide have lost more than 
half their expression of IRF4 at 20nM 10N, whereas it takes about 50nM of 10N 
to reach 50% IRF4 expression in response to pOva.  This indicates that the 
strong TCR signal generated by pOva can compensate for or withstand a greater 
loss in Itk activity than the TCR signal generated by T4 peptide. 
 Given that altering TCR signal strength by using APLs results in 
differential Eomes expression, we formulated a dose-response curve for this 
transcription factor.  Similar to IRF4 expression, the sensitivity of OT-I CD8 T 
cells stimulated with T4 peptide is greater than that of pOva (Fig 2.5C).  Only at 
concentrations greater than 60nM 10N was Eomes expression affected in cells 
stimulated with pOva.  On the other hand, at concentrations between 20 and 
25nM 10N, cells stimulated with T4 peptide began losing Eomes expression.  
Interestingly, the amount of fluorescence increased by about 40% in cells 
stimulated with pOva in the presence of 30nM 10N compared with those cells 
stimulated in the absence of 10N (MnFI values of 1062 no inhibitor vs 1492 
30nM).  This suggests that decreasing Itk activity can dampen the strong signals 
91
produced by pOva.  The result of this is an increased expression of Eomes, 
strengthening the argument that Eomes expression in CD8 T cells is inversely 
proportional to TCR signal strength.   
 
TCR signal strength can be altered by NFAT activity resulting in the graded 
expression of IRF4 
  
 Itk is a critical regulator downstream of TCR signaling in T cells, linking 
membrane proximal events to major downstream pathways by activating PLCγ1.  
The generation of secondary messengers, IP3 and DAG, which are produced by 
PLCγ1, induces the MAPK cascade, NF-κB activation, and Ca2+ mobilization.  
One of the major defects in Itk-/- T cells is an uncoupling of TCR signaling with 
NFAT activity (118, 159).  Due to the graded IRF4 expression seen during Itk 
inhibition, we wanted to assess the ability of NFAT to transduce analog signals in 
stimulated CD8 T cells.  In order to examine NFAT activity on the expression of 
IRF4, we used the calcineurin inhibitor FK506.  OT-I CD8 T cells stimulated with 
pOva in the presence of increasing amounts of FK506 displayed a graded 
distribution of IRF4 (Fig 2.6A, left histograms).  For lower concentrations of 
FK506 (0.075, 0.15 and 0.3 nM), the expression of IRF4 changed very little in 
cells stimulated with pOva compared to cells stimulated in the absence of FK506.  
Even at the highest concentration of FK506, pOva-induced expression of IRF4 
remained above the levels of unstimulated cells.  This suggests that it takes 
substantial amounts of NFAT inhibition to alter the expression of IRF4.  Similarly,  
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Figure 2.6 
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Figure 2.6 TCR signal strength is altered by NFAT activity 
(A) OT-I CD8 T cells were stimulated with of pOva in the presence of an NFAT 
inhibitor.  The inhibitor concentrations, in nanomolar, used are indicated in the 
left panel of histograms.  Cells were harvested at 24 hours and subjected to an 
intracellular stain for IRF4 (left histograms) and Eomes (right histograms).   
(B) OT-I CD8 T cells were stimulated with of G4 peptide in the presence of an 
NFAT inhibitor.  The inhibitor concentrations, in nanomolar, used are indicated in 
the left panel of histograms.  Cells were harvested at 24 hours and subjected to 
an intracellular stain for IRF4 (left histograms) and Eomes (right histograms).   
For comparative purposes, the red histograms in each panel are unstimulated 
cells.  The triangle at the right indicates the concentration of NFAT inhibitor. 
Data are representative of 3 independent experiments. 
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Eomes expression in CD8 T cells stimulated with pOva in the presence of low 
concentrations of FK506 (0.075, 0.150. 0.3nM) was not considerably altered but 
remained detectable above background levels (Fig 2.6A, right histograms).  
Intriguingly, the same concentrations of FK506 (0.6 and 1.2nM) that caused a 
decrease in IRF4 expression in cells stimulated with pOva resulted in an increase 
in Eomes expression.  This suggests that NFAT activity is required for full 
expression of IRF4, and further provides evidence that IRF4 regulates Eomes 
expression. 
 The analog response observed when CD8 T cells are stimulated with 
pOva in the presence of FK506 was not as impressive as we had expected.  We 
reasoned that a lower affinity peptide would allow us to more readily resolve the 
effect that NFAT activity had on TCR signal strength.  Therefore, we repeated 
these experiments using the G4 peptide.  When OT-I CD8 T cells were 
stimulated with G4 peptide in the presence of FK506, we observed a much more 
pronounced analog response as demonstrated by IRF4 expression (Fig 2.6B, left 
histograms).  The influence of FK506 on IRF4 expression was seen at 
concentrations as low as 0.15nM and continued to the highest non-toxic dose 
(1.2nM).  Interestingly, at 1.2nM FK506 an almost complete loss of IRF4 
expression was observed, suggesting that NFAT activity is required for IRF4 
expression when TCR signal strength is low.  We were unable to detect any 
appreciable change in Eomes expression at low concentrations of FK506 (Fig 
2.6B, right histograms).    At 0.6 and 1.2nM FK506, we noticed the levels of 
Eomes starting to decrease despite the reduction in IRF4 expression.  This was 
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somewhat surprising because we are unaware of any direct regulation of Eomes 
induction by NFAT.  Nonetheless, the data from these experiments demonstrate 
the ability of NFAT activity to transmit an analog signal from the TCR in response 
to both strong and weak signal strength. 
 
Discussion 
 
The information that a T cell receives to induce activation can most aptly 
be conveyed as one of signal strength.  The notion of TCR signal strength is 
frequently used to describe the development of T cells in the thymus, whereby 
‘too strong’ signals lead to negative selection, ‘just right’ signals lead to positive 
selection, and no signal leads to death by neglect.  In this context, a suitable T 
cell population can arise that will provide adequate protection to the host.  
Altering the strength of TCR signaling can completely change the developmental 
dynamics required for an appropriate T cell repertoire (119, 165, 260).  Once T 
cell development is complete, TCR signal strength influences the fate of CD4 T 
cell differentiation into TH1 vs TH2 cells and controls TH17 cell responses (120, 
261, 262).  The important determinants of TCR signal strength include, but are 
not limited to: the potency of TCR – pMHC interactions, the duration of TCR – 
pMHC interactions, the density of pMHC presentation, and the activity of 
signaling mediators.   
In our studies, we employ two experimental models of TCR signal 
strength, potency of TCR – pMHC interactions and activity of signaling 
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mediators, to show that a CD8 T cell integrates digital and analog signals to 
promote activation.  Several lines of evidence support such a conclusion.  CD8 T 
cells stimulated with decreasing concentrations of a given peptide display a 
uniformly similar pattern of expression for TCR responsive genes, such as IRF4 
and CD69.  T cell activation persists until a critical concentration threshold is 
reached; at this point T cells cease to respond.  This implies that T cells can be 
activated in an on/off manner, similar to a light switch, and is consistent with 
current models that propose T cell responses occur in a digital manner (120, 121, 
263).  Indeed, a preponderance of research indicates that several pathways 
downstream of the TCR, notably the NF-κB and MAPK pathways, can mediate 
digital activation of T cells (88, 122, 249).   
On the other hand, if CD8 T cells are exposed to altered peptide ligands 
(APLs) of varying potency, and therefore varying signal strength, the response 
changes from all digital to partially digital and partially analog.  For example, the 
cell surface markers CD69 and CD44 display a digital pattern of expression.  
This makes sense because expression of CD69 and CD44 require the actions of 
AP-1 or NF-κB and AP-1, respectively (72, 264, 265).  Conversely, the 
transcription factor network established during T cell activation is skewed in 
response to varying TCR signal strength.  This is best documented by the 
changes in the expression of IRF4, where strong TCR signals lead to more IRF4 
and weak TCR signals generate less IRF4.  It is not completely clear which 
transcription factors regulate IRF4 expression but it is clear that TCR signal 
strength is important.  
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The identification of digital and analog signals simultaneously emanating 
from the TCR immediately prompts the question – how is this regulated?  To 
examine this, we conducted experiments that involved modulating the activity of 
signaling mediators.  The selection of potential targets that can mediate an 
analog response is limited, largely because of the essential requirements for so 
many components of the TCR signaling cascade.  For instance, both Src and 
Syk family kinases have major developmental blocks in thymopoiesis, which is 
likely due to the complete absence of TCR signaling (123, 124, 266, 267).  This 
is demonstrated in T cells that genetically lack Zap-70 (125, 268).  Crosslinking 
the TCR in these T cells results in the complete ablation of downstream signaling 
events, as evidenced by lack of phosphorylated PLCγ1, nonexistent Ca2+ 
mobilization, and no IL-2 production.  By comparison, the defect in Itk-deficient T 
cells is relatively mild.  In the absence of Itk, T cells display diminished TCR 
signaling with mild defects in PLCγ1 phosphorylation, decreased NFAT activity, 
and reduced IL-2 production.  Because of the inherent developmental defects 
associated with Itk deficiency, we sought to tune Itk activity with a 
pharmacological inhibitor.  In order to eliminate toxicological bias of the inhibitor, 
only cells that expressed CD69 were included for analysis.  Despite the finite 
range of useful concentrations, IRF4 expression was graded in CD8 T cells 
stimulated with given peptides in the presence of increasing concentrations of 
inhibitor.  There are several important implications of this finding.  First, it 
demonstrates that IRF4 expression is sensitive to Itk activity.  Second, it 
demonstrates that Itk activity is capable of propagating analog signals from the 
98
TCR.  Third, despite the reduction in IRF4 expression, CD69 expression 
remained intact on all cells.  Fourth, it phenocopies the results obtained through 
the stimulation of T cells with altered peptide ligands of varying potency.  Finally, 
the data is in line with previously published work describing the ability of Itk to act 
as a rheostat (126, 269).   
The relationship between Itk and NFAT has been firmly established.  Itk 
functions upstream of the primary signaling pathways in T cells.  The majority of 
these pathways have been shown to transmit digital signals in response to TCR 
stimulation (88, 127, 249).  Consistent with this idea, we find that CD69 is 
expressed in a digital manner.  Very little data exists on whether the NFAT 
pathway responds in a digital or analog manner.  Using a non-competitive 
inhibitor of NFAT, the activity of this transcription factor can be modulated in 
response to various concentrations of the inhibitor.  CD8 T cells exposed to 
strong TCR signals in the presence of increasing NFAT inhibition exhibit an 
altered transcription factor profile exemplified by analog control of IRF4 
expression.  This is especially true at higher amounts of inhibition.  Moreover, the 
result is more pronounced in cells that were stimulated with weak TCR ligands.  
This suggests that high TCR signal strength can overcome NFAT inhibition to a 
greater extent than low strength TCR signals.  Overall, our experiments suggest 
that NFAT is capable of transmitting analog signals that result in the graded 
expression of IRF4.  
With this understanding, we constructed a model to describe the manner 
in which T cells are activated.  The model in Figure 2.7 depicts the pulse curve of  
99
T cell activation as a function of signal strength.  It compares the two types of T 
cell responses that pass through digital and analog mediators. Digital and analog 
responses occur once a critical activation threshold is overcome.  Digital signals 
use on - off mediators such as ZAP-70 to culminate in bi-modal responses like 
CD69 expression.  These responses are independent of TCR signal strength.  
Oppositely, analog responses are dependent on TCR signal strength.  Analog 
signals use mediators that do not function as on - off switches like Itk.  They are 
tunable dials.  As TCR signal strength increases so too does the T cell response, 
as evident by graded IRF4 expression. 
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Figure 2.7 
 
 
 
 
 
 
 
Figure 2.7 Model of T cell activation in response to TCR signal strength 
Upon reaching a critical threshold, signals pass through ZAP-70 to generate 
digital expression of CD69, whereas Itk acts as a digital to analog converter 
producing the graded expression of IRF4. 
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Materials and Methods 
 
Mice 
 
Mice were bred and housed under specific pathogen-free conditions at the 
University of Massachusetts Medical School (UMMS) in accordance with 
institutional animal care and use committee guidelines. OT-I TCR transgenic 
Rag1−/− mice were purchased from Taconic.  Mice were euthanized between 8 
and 12 weeks of age. 
 
Cell Culture Conditions 
 
Spleens from OT-I Rag1-/- mice were harvested and processed using aseptic 
technique in a laminar flow hood.  Red blood cells were lysed with ammonium 
chloride for 5 minutes at room temperature.  Pure splenocytes were filtered and 
counted using a Cellometer Auto T4 cell counter (Nexcelom Bioscience).  
Splenocytes with greater than 85% viability were seeded at 1.25x106 cells/mL in 
96-well round bottom tissue culture plates.  Complete media consisted of RPMI-
1640 base, 10% heat-inactivated FBS, 100 U/mL penicillin, 100 ug/mL 
streptomycin, 100 mM L-glutamine, 100 µM non-essential amino acids, 50 µM 2-
ME, and 10 µM HEPES buffer.  Cells were incubated for the indicated time points 
at 37°C, 5% CO2 in a water-jacketed incubator. 
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Peptides  
  
The peptides used are listed in Table 2.1 and were synthesized to greater than 
90% purity by 21st Century Biochemicals.  Peptides that activated OT-I CD8 T 
cells were used at concentrations sufficient to induce maximal CD69 expression, 
unless otherwise indicated.  Control peptides or peptides that do not sufficiently 
induce CD69 expression were used at 10uM. 
 
Antibodies and staining 
 
CD8-PE- Texas Red (PETR) and Live/Dead Violet were purchased from 
Invitrogen.  CD44-v500 and CD69-PE Cy7 were purchased from BD 
Biosciences.  Eomes-FITC, Eomes-PerCP eFluor710, IRF4-Allophycocyanin 
(APC), IRF4-phycoerythrin (PE), and TCR-β–APC eFluor780 were purchased 
from eBioscience.  Cells were harvested at the indicated time points and washed 
with 2% FBS/PBS.  Cells were incubated with the indicated surface stains for 20 
minutes at 4°C.  Cells were washed with 2% FBS/PBS, fixed and permeabilized 
using the FoxP3 fixation and permeabilization kit (eBiosciences) according to the 
manufacturer’s protocol.  Flow cytometry was performed using a BD LSRII (BD 
Biosciences).  Analysis was done using FlowJo (TreeStar) and Prism 
(GraphPad) software.  In all experiments, cells were gated using doublet 
discrimination, Live Dead staining, and fluorescence minus one (FMO) controls. 
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Reagents 
 
The Itk inhibitor 10N was synthesized at the National Institutes of Health and was 
kindly provided by Jian-kang Jiang and Craig Thomas (Chemical Genomics 
Center, NIH).  The NFAT inhibitor FK506 was purchased from Calbiochem.  The 
concentrations of inhibitors used are indicated in the text and figure legends. 
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Table 2.1 Peptide variants presented by MHC Class I  
The table above depicts the peptides used to ligate the TCR on OT-I CD8 T cells.  
The abbreviation is listed in the first column with the corresponding amino acid 
sequence in the second column.  The third column quantifies the potency relative 
to pOva of each peptide’s ability to stimulate CD69 expression on OT-I CD8 T 
cells (44, 128, 129, 257, 258).  The fourth column is the concentration of peptide 
used in experiments unless otherwise indicated in the figure legend.  P815 and 
m97 are control peptides that do not stimulate OT-I CD8 T cells.   
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Table 2.1 
 
 
 
  
  
 
 
 
 
 
Chapter 3:  
Itk is a negative regulator of mast cell activation 
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Chapter III Attributions 
The material in chapter III has been submitted for publication and consists of a 
collaboration between Yoko Kosaka [YK], Markus Falk [MF], Stefan Schattgen 
[SS], and myself [JE].  The specific contributions for each figure are as follows: 
Figure 3.1 [YK], Figure 3.2 [YK and JE], Figure 3.3 [YK and JE], Figure 3.4 [YK 
and MF], Figure 3.5 [MF and SS], and Figure 3.6 [MF and JE]. 
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Introduction 
 
 Upon activation, mast cells secrete an extensive variety of effector 
molecules, including biogenic amines, enzymes, lipid metabolites, and cytokines.  
Many of these mediators are preformed and stored in granules, while others are 
newly synthesized.  Historically, mast cell-derived products are responsible for an 
assortment of allergic responses ranging from localized wheal-and-flare reactions 
to systemic anaphylaxis (75, 130).  More recently, mast cells have been linked to 
atherosclerosis, obesity, and cancer (124, 215, 216).  In addition, the diversity of 
mediators that are released when mast cells are stimulated puts them in a prime 
position to regulate the adaptive immune response to pathogens (37, 131).  In 
light of such observations, the biochemical signaling events involved in 
generating effector responses in mast cells is of significant interest.   
Mast cells can be activated through the signaling of many cell surface 
receptors, including the high affinity Fc receptor for IgE (FcεRI).  Aggregation of 
the FcεRI triggers a cascade of events that is highly reminiscent of the signals 
elicited by other multi-chain immune recognition receptors, such as the antigen 
receptors on T cells and B cells (the TCR and BCR, respectively) (121, 231, 
232).  Upon FcεRI crosslinking, two functionally complementary pathways are 
activated by the Src family kinases, Lyn and Fyn.  Lyn acts by phosphorylating 
the β and γ  chain immunoreceptor tyrosine-based activation motifs (ITAMs) of 
FcεRI, resulting in the recruitment and activation of Syk.  Activation of Lyn and 
Syk lead to the assembly of a membrane-associated signaling complex that is 
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nucleated by LAT and promotes the activation of PLCγ.  As in lymphocytes, 
PLCγ activation is a key event, leading to the production of inositol-1,4,5-
triphosphate (IP3) and diacylglycerol (DAG), thereby linking receptor-proximal 
events to major downstream pathways that regulate gene expression.  
Like Lyn, Fyn also associates with FcεRI and is activated as a result of 
FcεRI crosslinking (132-134, 230).  Fyn phosphorylates the adaptor molecule 
Gab2, thereby recruiting the p85 subunit of PI3K to the membrane.  PI3K activity 
then produces membrane phosphatidylinositol-3,4,5-trisphosphate (PIP3), 
leading to the recruitment of PH domain-containing proteins, such as PLCγ and 
Tec family kinases.  Despite the distinct biochemical nature of the Lyn-and Fyn-
dependent signals, it is clear that crosstalk exists between these two pathways 
and that both are essential for optimal FcεRI signaling.  The activation of 
mitogen-activated protein kinases (MAPK), NFAT, and NF-κB has all been 
shown to require the activity of both branches of the FcεRI signaling network 
(121, 270).    
 Previous studies in T cells, B cells, and mast cells have demonstrated that 
Tec family kinases are integral components of antigen receptor signaling 
pathways (72, 121, 135).  The predominant function of Tec family kinases is the 
phosphorylation and activation of PLCγ.  In T cells, Itk localizes to the membrane 
by associating with the LAT complex and by binding to PIP3.  This brings Itk into 
proximity with its target substrate, PLCγ1.  Thus, T cells lacking Itk exhibit 
reduced PLCγ1 phosphorylation, leading to impaired IP3 production, diminished 
Ca2+ mobilization, and decreased NFAT activation.  The reduction in PLCγ1 
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phosphorylation also decreases activity in the MAPK cascade.  The 
consequence of these signaling defects is severely impaired T cell effector 
function, which is highlighted by the susceptibility of Itk-/- mice to various 
pathogenic infections (136-139, 160, 161).  Based on these data, it is well 
accepted that Itk has a positive regulatory role in TCR-mediated signaling 
pathways.  
In mast cells, as in B cells, the Tec kinase Btk has a similar positive 
signaling role in the activation of PLCγ in response to antigen receptor 
stimulation.  For instance, Btk-deficient mast cells exhibit multiple defects 
following FcεRI activation, including impairments in degranulation, production of 
leukotrienes, and synthesis of cytokines (140, 233, 235-237).  Biochemical 
studies show that PLCγ2 activation, IP3 generation, and Ca2+ mobilization are all 
decreased in mast cells lacking Btk.   
In addition to Btk, mast cells express other Tec family members: Itk, Rlk, 
and Tec (141-145, 234, 271) (and our unpublished observations).  To date, the 
biochemical function(s) of these additional Tec kinases in mast cell signaling 
pathways has not been well addressed.  Initial data suggested the likelihood that 
Itk participates in mast cell signaling based on the observation that Itk is recruited 
to the membrane and phosphorylated in response to FcεRI stimulation (143, 
240).  Additional, studies have examined the function of Itk in vivo, using models 
of allergic airway responsiveness.  Forssell and colleagues indirectly investigated 
Itk-deficient mast cells by challenging Itk-/- mice with an airway allergen and 
looking for signs of inflammation (146-149, 241).  In this report, Itk-/- mice 
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exhibited significant impairments in lung mast cell degranulation following antigen 
challenge in the airways.  Interestingly, a direct comparison of Itk-/- mice with Btk-
/- mice in this system indicated that the lack of Itk led to a more severe defect 
than that seen in the absence of Btk.  In contrast, a more recent study by Iyer 
and colleagues used an in vivo reconstitution model where wild-type or Itk-/- bone 
marrow-derived mast cells (BMMC) were adoptively transferred into mice lacking 
mast cells (150, 244).  Here, mice reconstituted with Itk-/- BMMC demonstrated 
equivalent levels of airway responsiveness to mice reconstituted with wild-type 
BMMC indicating that Itk was not required for mast cell degranulation.  
Interestingly, they also showed that Itk-/- mast cells secreted elevated levels of 
cytokines following FcεRI stimulation, however no apparent signaling defects 
were observed.  Therefore the role of Itk in mast cell activation remains 
incompletely defined. 
In our studies, we examine mast cell responses in vitro to determine 
whether the absence of Itk has an intrinsic effect on mast cell function.  We show 
that freshly isolated peritoneal mast cells (PMCs) from Itk-deficient mice have 
dramatically increased levels of IgE on their surface.  This corresponds to an 
increase in cytokine secretion following IgE crosslinking.  Strikingly, we also find 
that Itk-deficient BMMCs are functionally hyperresponsive, exhibiting enhanced 
cytokine production in response to FcεRI stimulation.  Analyses of biochemical 
events downstream of FcεRI show increased levels of PLCγ2, Erk1 and -2 
phosphorylation, Ca2+ mobilization, and NFATc1 activation in Itk-/- versus wild-
type mast cells.  To account for this phenotype, we demonstrated an inducible 
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interaction between Itk and SHIP-1 following FcεRI stimulation.  Furthermore, we 
showed that Itk could phosphorylate Dok-1, Dok-2, and SHIP-1 in vitro as well as 
co-localize with a multi-molecular negative signaling complex upon FcεRI 
stimulation.  Taken together, these observations support the conclusion that Itk is 
important for the formation of an inhibitory signaling pathway that represses 
cytokine production following mast cell activation.  
 
Results  
 
Augmented levels of IgE on the surface of peritoneal mast cells from Itk-/- mice 
 
We first assessed the phenotype of mast cells isolated from Itk-/- mice ex 
vivo.  Total peritoneal exudate cells (PECs) were collected and stained with anti-
c-kit and anti-IgE antibodies (Fig. 3.1A).  c-kit+ PECs from Itk-/- mice consistently 
showed higher levels of anti-IgE staining compared to WT PECs.  Given that Itk-/- 
mice exhibit spontaneously high levels of IgE in the serum and that IgE alone 
induces upregulation of FcεRI on mast cells, this finding was not surprising (151-
153, 161, 272).   
We then assessed the functional responsiveness of PMCs from Itk-/- and 
WT mice by crosslinking the FcεRI.  To do this, c-kit+ cells were isolated from 
total peritoneal exudate by magnetic bead selection.  Toluidine blue staining of 
the  resultant  cells  confirmed  a  highly  pure  population of  mast cells (data not  
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Figure 3.1 
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Figure 3.1 Peritoneal mast cells from Itk-/- mice show elevated surface IgE 
and enhanced responsiveness to FcεRI stimulation 
(A)  PECs were stained with anti-IgE-FITC and anti-c-kit-PE and analyzed by 
flow cytometry.  Plots shown are gated on live SSChi cells. 
(B)  WT (black bars) or Itk-/- (white bars) c-kit+ PECs were isolated by positive 
selection using magnetic beads.  After overnight incubation, cells were stimulated 
with plate-bound anti-IgE at the indicated concentrations.  Cytokines were 
detected by ELISA 20 hrs post IgE crosslinking. (*below limit of detection: IL-4, 
0.03 ng/mL; IL-6, 0.016 ng/mL; IL-13, 0.02 ng/mL).  Data shown are 
representative of 4 independent experiments. 
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shown).  When Itk-/- PMCs were stimulated with plate-bound anti-IgE antibody, 
IL-4 and IL- 13 secretion was readily observed.  In contrast, WT PMCs produced 
amounts of cytokine that were generally below the level of detection (Fig. 3.1B).  
Unlike IL-4 and IL-13, IL-6 secretion by both types of PMCs was detectable.  
However, Itk-/- PMCs showed a slight increase in IL-6 release upon IgE 
crosslinking.  The elevated cytokine response exhibited by Itk-/- mast cells is likely 
due to enhanced mast cell stimulation generated by the high levels of IgE/FcεRI 
complex on the surface of these cells.  
 
Itk-/- BMMCs appear developmentally normal and produce a normal 
degranulation response 
 
 To examine mast cell responses in the absence of the environmental 
influences present in Itk-/- mice, we generated mast cell cultures from bone 
marrow progenitors (BMMCs).  As expected, Itk is expressed in WT BMMCs and 
is absent from Itk-/- BMMCs (Fig. 3.2A).  We also found no detectable 
compensatory changes in Btk expression in Itk-/- BMMCs.  Importantly, and in 
contrast to the ex vivo data, Itk-/- BMMCs showed no consistent difference in the 
expression levels of FcεRI compared to WT BMMCs.  This enabled a functional 
comparison of cells with similar levels of surface FcεRI (Fig. 3.2B).  
To address whether the lack of Itk in mast cells affected degranulation, 
BMMCs were first sensitized with anti-DNP IgE then incubated with varying 
amounts of DNP-HSA to crosslink the receptor.  Degranulation, as assessed by  
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Figure 3.2 
 
 
117
Figure 3.2 Degranulation responses of WT and Itk-/- BMMCs are similar 
(A) Itk protein in WT and Itk-/- BMMC lysates was assessed by immunoblotting 
with anti-Itk antibody.  The membrane was reprobed with anti-Btk and anti-PLC-
γ2 antibodies.  
(B) WT (solid line) or Itk-/- (dotted line) BMMCs were blocked with 2.4G2 for 5-10 
min, then stained with anti- FcεRI or control IgG (thick grey line) for 20 min, and 
analyzed by flow cytometry.   
(C) BMMCs were sensitized with IgE (SPE-7) for 4 hrs, followed by incubation 
with the indicated doses of DNP-HSA.  After 30 min, β-hexosaminidase release 
was assessed (WT, solid line; Itk-/-, dotted line).  Data shown are representative 
of 4 independent experiments. 
(D) Assay was performed as in (C) but with H1-DNP-α-26 IgE for sensitization.  
Data shown are representative of 2 independent experiments. 
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β-hexosaminidase release, was similar between WT and Itk-/- mast cells (Fig. 
3.2C).  However, we consistently observed slightly higher ‘background’ 
degranulation (no antigen) in Itk-/- BMMCs compared to WT BMMCs.  We 
interpreted this as an indication that Itk-/- mast cells were hypersensitive to the 
low amount of signal generated by the binding of the SPE-7 clone (anti-DNP IgE 
antibody) to the FcεRI.  A review of the literature confirmed our suspicions, as 
this IgE clone has been suggested to induce some receptor signaling even in the 
absence of antigen-mediated crosslinking (154, 155, 273).  Accordingly, when 
these experiments were repeated using the anti-DNP IgE clone H1-DNP-α-26 the 
augmented ‘background’ degranulation disappeared (Fig. 3.2D) (156, 274).  
Therefore, maximal FcεRI-mediated degranulation is similar in magnitude and 
dose response to antigen in Itk-/- and WT BMMCs.  However, Itk-/- mast cells 
have a heightened sensitivity to IgE binding alone following SPE-7 incubation. 
 
Increased cytokine production by Itk-/- BMMCs upon FcεRI stimulation 
 
 In T cells, a deficiency in Itk leads to impaired production of cytokines 
following TCR stimulation.  With this in mind, we assessed the ability of Itk-/- mast 
cells to produce cytokines upon FcεRI stimulation.  To our surprise, we 
consistently found that the secretion of cytokines (IL-4, IL-6, and IL-13) by Itk-/- 
BMMCs was higher than that produced by WT BMMCss (Fig. 3.3A).  
Furthermore, incubation  of  BMMC with IgE (SPE-7), in  the absence  of antigen,  
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Figure 3.3 
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Figure 3.3 Increased cytokine production by Itk-/- BMMC upon FcεRI 
stimulation 
(A) WT (black bars) or Itk-/- (white bars) BMMC were incubated alone (none), or 
with 1 µg/mL IgE for 4 hrs with (IgE+Ag) or without (IgE) 30 ng/mL DNP-HSA 
(Ag) for 20 hrs.  Supernatants were analyzed for cytokines by ELISA; limits of 
detection:  IL-4, 0.002 ng/mL; IL-6, 0.008 ng/mL; IL-13, 0.02 ng/mL.  Data shown 
are representative of 4 independent experiments. 
(B) WT (black bars) or Itk-/- (white bars) BMMC were incubated as in (A), but cells 
were harvested 4 hrs after addition of Ag.  Amounts of cytokine mRNA were 
determined by quantitative RT-PCR, and are expressed as arbitrary units (A.U.) 
relative to β2-microglobulin mRNA.  Data shown are representative of 2 
independent experiments. 
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stimulated higher levels of cytokine production from Itk-/- mast cells compared to 
WT mast cells.  This observation correlated with the degranulation response.   
 Cytokines secreted from mast cells can be stored as preformed mediators 
or be newly synthesized in response to signal transduction.  The release of 
cytokines in both situations can be mediated through FcεRI stimulation.  To 
distinguish between the two events, we assessed the levels of cytokine mRNA in 
WT and Itk-/- mast cells by quantitative real-time PCR.  As shown in Figure 3.3B, 
the pattern of cytokine transcript levels mirrored the pattern of cytokine secretion.  
Itk-/- BMMCs consistently transcribed more mRNA for IL-4, IL-6, and IL-13 than 
WT BMMCs in response to FcεRI stimulation.  Thus, the augmented cytokine 
secretion observed in the absence of Itk is due to increases in the de novo 
synthesis of these cytokines.  These data also rule out the possibility that the 
increased cytokine production by Itk-/- BMMCs is an indirect effect of protease-
mediated cytokine degradation.  These results indicated the existence of a 
signaling defect in Itk-/- mast cells.  
 
Enhanced FcεRI-induced signaling in Itk-/- BMMCs    
 
 A major function of Itk in T cells is to phosphorylate and activate PLCγ1.  
Consequently, in Itk-/- T cells, phosphorylation of PLCγ1 following TCR 
stimulation is reduced.  To determine whether PLCγ phosphorylation is affected 
by the loss of Itk in mast cells, BMMCs were stimulated by FcεRI crosslinking 
and lysates were immunoblotted with phospho-specific antibodies against PLCγ1  
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Figure 3.4 
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Figure 3.4 Enhanced FcεRI-induced activation of signaling pathways in Itk-/- 
BMMCs 
(A) BMMCs were sensitized with 0.5 µg/mL IgE and incubated with 100 ng/mL 
DNP-HSA for the indicated times.  Lysates were immunoblotted with anti-
phospho-PLC-γ1 (upper left), anti-phospho-PLC-γ2 (lower left), anti-phospho-
ERK1/2 (upper right), or anti-phospho-IκBα (lower right).  Membranes were then 
stripped and reprobed with antibodies to detect total protein levels. Numbers 
under left panels represent densitometric values of phospho-PLC-γ bands 
normalized to total PLC-γ (loading), relative to the value for WT cells at the 0 time 
point.  Data shown are representative of 3 independent experiments. 
(B) WT (solid line) or Itk-/- (dotted line) BMMCs were sensitized with IgE and 
loaded with Fluo-3 and Fura Red.  DNP-HSA (100 ng/mL), at 30 sec, and 
ionomycin (2 mM), at 8 min, were added and fluorescence was assessed by flow 
cytometry.  Data shown are representative of 4 independent experiments.   
(C) WT (black bars) or Itk-/- (white bars) BMMCs were incubated for 4 hrs with 0.5 
µg/mL IgE and stimulated for 0 or 15 min with 100 ng/mL DNP-HSA.  Nuclear 
extracts were isolated and subjected to NFATc1 ELISA assay.  Data shown are 
representative of 3 independent experiments. 
(D) WT or Itk-/- BMMCs were sensitized with 1 µg/mL IgE for 4 hrs and stimulated 
for 4 hrs with DNP-HSA.  Lysates were probed for phospho-Erk1/2 or PI3-kinase 
p85 as a control (left panel), or phospho-PLCγ2, phospho-p38, phospho-Lyn/Fyn, 
and GAPDH as a control (right panel).  Data shown are representative of 2 
independent experiments. 
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(E) WT or Itk-/- BMMCs were stimulated as described above for the indicated 
time. Lysates were probed for phospho-PLCγ2, phospho-Erk1/2 and GAPDH as 
a control.  Data shown are representative of 2 independent experiments. 
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and PLCγ2 (Fig. 3.4A).  Although in some experiments Itk-/- mast cells showed a 
slight enhancement in PLCγ1 phosphorylation compared to WT mast cells, this 
effect was not consistently observed.  In contrast, PLCγ2 phosphorylation was 
reproducibly increased in Itk-/- versus WT BMMCs following stimulation.   
Since Ca2+ mobilization is a response that occurs downstream of PLCγ–
induced IP3 generation, we assessed whether intracellular Ca2+ levels were 
affected by the increased PLCγ2 phosphorylation observed in Itk-/- BMMCs.  As 
shown in Fig. 3.4B, Itk-/- BMMCs exhibit an elevated rise in intracellular Ca2+ 
following FcεRI stimulation compared to WT BMMCs.  This increased Ca2+ 
response led to enhanced activation of NFAT in stimulated Itk-/- BMMCs, 
indicating that the observed increases in PLCγ phosphorylation and Ca2+ 
mobilization lead to functionally significant changes in transcription factor activity 
(Fig. 3.4C).  The effects on downstream signaling pathways at these time points 
were selective, however.  The activation of ERK and NF-κB pathways was not 
detectably altered in Itk-/- versus WT BMMCs at periods up to 15 minutes 
following activation (Fig. 3.4A).   
To reconcile the apparently modest effects on signaling pathways with the 
more robust effects on cytokine production in Itk-/- BMMC, we considered 
whether alterations in signaling might occur at time points later than those initially 
assessed.  Therefore, we stimulated WT and Itk-/- BMMC for 4 hours and then 
prepared lysates for biochemical analysis.  These experiments showed that Itk-/- 
BMMCs   sustain   elevated   levels  of  PLCγ2  phosphorylation,  Lyn/Fyn 
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phosphorylation, and phosphorylation of ERK1/2 compared to WT BMMCs for 
several hours following activation (Fig. 3.4D-E).   
 
Itk binding to SHIP-1 is mediated by the Itk SH2 and SH3 domains 
 
Given the aberrant regulation of cytokine production and the presence of a 
signaling defect in Itk-/- mast cells, we postulated that Itk could participate in an 
inhibitory pathway.  To identify a mechanism for the inhibitory role of Itk on mast 
cell signaling, we considered the SHIP (SH2-containing inositol phosphatase) 
family of regulators.  SHIP-1 and SHIP-2 have been implicated in the negative 
regulation of various signaling pathways, including FcεRI signaling in mast 
cells(117, 275-278).  Further, mast cells lacking SHIP-1 produce elevated levels 
of cytokines following activation(157, 279, 280).  These data, together with 
previous studies documenting an interaction between SHIP-1 and the Tec family 
kinase, Tec, led us to investigate a potential interaction with Itk and subsequent 
regulation of the SHIP pathway (126, 158).  To test this, we first co-expressed Itk 
and SHIP-1 in 293T cells.  When SHIP-1 was immunoprecipitated from lysates of 
pervanadate-treated cells, we observed that Itk was co-precipitated (Fig. 3.5A).  
To identify the Itk protein domains involved in this interaction, pull-down 
experiments were performed using lysates of RBL-2H3 mast cells and GST-
fusion proteins containing individual Itk domains.  These experiments 
demonstrated that the SHIP-1 present in the RBL-2H3 cells bound to both the Itk 
SH2  and  SH3  domains.   However,  binding  to  the  Itk  SH2  domain  was only  
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Figure 3.5 
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Figure 3.5 Itk binds to and can phosphorylate SHIP-1 
(A) 293T cells were transfected with expression vectors encoding GFP, Itk, 
SHIP-1, or both Itk and SHIP-1.  After 24 hrs cells were left untreated or were 
stimulated with pervanadate as indicated.  SHIP-1 was immunoprecipitated and 
filters were probed with antibodies to Itk.  Lane at far right indicates Itk levels in 
the whole cell lysate. 
(B) RBL-2H3 mast cells were left untreated, or were sensitized with 1 µg/mL IgE 
for 4 hrs and then stimulated with 100 ng/mL DNP-HSA for the indicated times.  
Lysates were incubated with beads containing GST-fusion proteins of the Itk SH2 
domain (SH2), the Itk SH3 domain (SH3), the mutated Itk SH2+SH3 domains 
(SH23*), or GST alone (GST).  Bound SHIP-1 was detected by immunoblotting 
with anti-SHIP-1 antibodies.  Data shown are representative of 3 independent 
experiments. 
(C) WT BMMCs were left untreated, stimulated with IgE alone, stimulated with 20 
ng/mL SCF for 4 hrs, or sensitized with 1 µg/mL IgE (4 hrs) and stimulated with 
100 ng/mL DNP-HSA (IgE+Ag) for the indicated time points.  Lysates were 
incubated with the Itk GST-SH2 domain fusion protein, and bound SHIP-1 was 
detected with anti-SHIP-1 antibodies.  Where indicated, the Itk GST-SH2 fusion 
protein was pre-incubated with 3 mM of a competitive phospho-peptide (AC-
ADpYEPP-NH2) prior to incubation with cell lysates.  
(D) Sf9 insect cells were infected with baculoviruses expressing WT Itk (Itk WT) 
or a kinase-inactive Itk mutant (Itk K390R) together with viruses expressing Dok-
1 (left panel), Dok-2 (middle panel) or SHIP-1 (right panel).  Sf9 cells were 
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harvested after 3 days. Cell lysates were probed with anti-phosphotyrosine 
antibody (top panels) or antibodies to Itk, Dok-1, Dok-2, or SHIP-1 (bottom 
panels). 
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detected when the RBL cells were activated prior to lysis (Fig. 3.5B).  Single 
amino acid substitutions in the ligand-binding pockets of the Itk SH2 and SH3 
domains (SH23*) prevented binding to SHIP-1 (Fig. 3.5B).  In addition, binding of 
SHIP-1 to the Itk SH2 domain was blocked by prior incubation of the SH2 domain 
with a phospho-peptide ligand, AC-ADpYEPP-NH2 (Fig. 3.5C).  This peptide 
binds to the canonical phospho-tyrosine binding pocket of the Itk SH2 domain 
(158, 281).   
SHIP-1 binds to LAT and recruits ‘downstream of kinase’ molecules, Dok-
1 and Dok-2, to form an inhibitory complex in T cells (159, 282).  We 
hypothesized that Itk could potentially directly phosphorylate SHIP-1, Dok-1, or 
Dok-2, thereby contributing to the activity of this complex.  For these 
experiments, Itk was co-expressed with SHIP-1, Dok-1, or Dok-2 in insect cells 
using baculovirus constructs.  As a negative control, each potential substrate was 
also co-expressed with a kinase-inactive form of Itk.  As shown in Figure 3.5D, 
wild type Itk, but not kinase-inactive Itk, was able to phosphorylate SHIP-1, Dok-
1, and Dok-2.   
 
Itk co-localizes with the SHIP-1 complex after mast cell activation 
 
To examine whether Itk subcellular localization is regulated by mast cell 
activation, we performed confocal microscopy on wild type BMMCs.  In 
unstimulated BMMCs, Itk is diffusely distributed in the cytosol, whereas LAT is 
membrane-localized, as expected (Fig 3.6A,C).  Following activation by FcεRI  
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Figure 3.6 
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Figure 3.6 Itk co-localizes with components of the SHIP-1 complex 
following FcεRI stimulation 
WT BMMCs were left untreated (A,C) or stimulated with IgE/DNP-HSA for 5 min 
(B, D, E-V).  Cells were fixed, permeabilized and stained with primary antibodies 
against Itk, LAT, SHIP-1, Dok-1, Dok-2, Shc, and Grb2 as indicated. Coverslips 
were incubated with secondary antibodies AlexaFluor 488 and AlexaFluor 568 
and analyzed by confocal microscopy. Right panel represent superimposed 
images (D,G,J,M,P,S,V).  Yellow color of overlay indicates co-localization of 
proteins. Data are representative of at least 2 independent experiments with at 
least 10 cells analyzed per antibody stain. 
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stimulation for 5 min, Itk is recruited to the cell membrane where it co-localizes 
with a substantial proportion of LAT molecules (Fig. 3.6B,D).  Furthermore, we 
observed Itk co-localization with components of the previously described 
inhibitory complex that includes SHIP-1, Dok-1, and Dok-2 (Figure 3.6E-M).  In 
addition, Grb2 and Shc were found to co-localize with SHIP-1 in activated 
BMMCs (Fig. 3.6N-S), supporting interactions between these proteins, as has 
been previously reported (159, 282, 283).  In contrast, a cytoplasmic kinase that 
is not involved in FcεRI signaling, Jak3, does not co-localize with Itk after mast 
cell activation (Fig 3.6T-V).  These results indicate that Itk is part of an inhibitory 
complex in mast cells stimulated through the FcεRI. 
 
Discussion 
 
In contrast to T and B lymphocytes, mast cells express high levels of Itk 
and Btk as well as low levels of Rlk and Tec.  It is well established that Itk 
deficiency in T cells drastically impairs TCR signaling, which is consistent with a 
positive regulatory function.  In this report, we describe a novel function for Itk as 
a negative regulator in mast cell activation.  This conclusion is based on the initial 
observation that Itk-deficient mast cells produce higher amounts of IL-4, IL-6, and 
IL-13 than WT mast cells following FcεRI stimulation.  We demonstrate that the 
elevated cytokine levels are due to aberrant de novo synthesis of cytokine 
transcript, an indication of a genuine signaling defect.  Consistent with these 
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findings, our biochemical studies indicate that PLCγ, ERK1/2, and LAT 
phosphorylation are elevated in activated mast cells lacking Itk.  This enhanced 
signaling, in turn, leads to enhanced Ca2+ mobilization and increased NFATc1 
activation.   
Interestingly, the most striking differences in phosphorylation of signaling 
proteins between WT and Itk-/- mast cells occur hours after FcεRI stimulation, 
rather than minutes.  These data support a role for Itk in a late-acting negative 
feedback pathway that dampens FcεRI-mediated activation.  Moreover, Itk-/- 
BMMCs share several striking similarities with BMMCs lacking the inositol 
phosphatase, SHIP-1.  For example, both SHIP-1-/- and Itk-/- BMMCs show an 
enhanced Ca2+ flux in response to FcεRI crosslinking.  Even more interesting, 
both types of cells respond to stimulation with anti-DNP IgE (SPE-7) in the 
absence of antigen (160, 161, 279).  These findings suggest that Itk may function 
in a SHIP-1-dependent inhibitory pathway downstream of the FcεRI.  
SHIP-1 signaling is mediated by the recruitment of adapter proteins, Dok-1 
and Dok-2 (162, 284).  Dok proteins have been identified as leukemia 
suppressors, and are substrates of the oncogene p210bcr-abl.  These adaptor 
proteins suppress activation signals by inhibiting the Ras-Erk pathway (160, 
285).  Similar to Itk-/- and SHIP-1-/- BMMCs, mast cells that lack Dok-1 also 
produce elevated levels of cytokine when stimulated with IgE alone (163, 164, 
286).  In addition, Dok-1 over-expression leads to reduced phosphorylation of 
Erk-1/2, as well as reduced TNFα production in RBL-2H3 cells stimulated by 
FcεRI crosslinking (165, 284). 
135
These striking similarities between mast cells lacking Itk, SHIP-1, and 
Dok-1 suggest that Itk may function in this inhibitory signaling pathway.  
Supporting this, we find that Itk is recruited to the cell membrane following FcεRI 
stimulation, where it co-localizes with SHIP-1, Grb2, Dok-1, and Dok-2.  Our 
biochemical studies suggest that, once recruited to the cell membrane, Itk 
associates with SHIP-1 via the Itk SH2 and SH3 domains.  In T cells, the SHIP-1 
complex is formed with the adaptor protein LAT.  Therefore, a similar mechanism 
may exist in mast cells, as we detect substantial co-localization of Itk and LAT 
upon FcεRI engagement.  SHIP-1 has also been reported to bind to 
phosphorylated ITAMs of the FcεRI beta subunit, indicating an additional 
pathway for recruitment of SHIP-1 to the activated FcεRI (166, 287).   
Biochemical interactions between components of a SHIP-1 signaling 
complex have been described in several systems.  For instance, tyrosine 
phosphorylation of Dok-1 is associated with increased binding of Grb2 (167, 
286).  In addition, LAT and SHIP-1 are required for TCR-induced Dok-2 tyrosine 
phosphorylation in T cells, with SHIP-1 acting as an adapter protein coupling 
Dok-2 to LAT (168, 282).  Finally the Tec kinase, Tec, forms a tri-molecular 
complex with SHIP-1 and Lyn in cells stimulated through cKit, and in T cells the 
Tec SH3 domain interacts with SHIP-1 and SHIP-2 (126, 169, 288).  Taken 
together, these data support the hypothesis that SHIP-1 signaling complexes can 
contain a Tec family tyrosine kinase, in addition to Lyn, Dok-1, Dok-2, and other 
adapter proteins. 
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The function of Itk following its interaction with SHIP-1 in activated mast 
cells remains to be determined.  At the FcεRI, SHIP-1 is activated by the Lyn 
kinase, however it is currently unclear whether Lyn is directly or indirectly 
mediating this effect (170, 171, 289).  One possibility is that Itk acts as an 
intermediary between Lyn and SHIP-1 and may directly phosphorylate SHIP-1.  
Along these lines, Itk phosphorylation of SHIP-1 could provide additional docking 
sites for the SH2 domains of other signaling molecules recruited to the SHIP-1 
complex.  Alternatively, Itk may not phosphorylate SHIP-1 in intact mast cells, but 
instead may bind to SHIP-1 and thereby be brought into proximity with other 
potential substrates, such as Dok-1 or Dok-2.  Thus far, our preliminary 
experiments have not demonstrated reduced phosphorylation of SHIP-1, at least 
at Y1020, in mast cells lacking Itk.  This may indicate that SHIP-1 is not a 
substrate of Itk in mast cells or that Itk phosphorylates SHIP-1 at a different site. 
Our data has also demonstrated that mast cells isolated from the 
peritoneum of Itk-/- mice have high levels of surface IgE.  Consequently, cytokine 
production by Itk-/- PMCs in response to IgE crosslinking was dramatically 
increased compared to WT PMCs.  This reflected, at least in part, an elevated 
signal generated through the high numbers of FcεRI on the surface of these 
cells.  Importantly, IL-4 and IL-13 secretion by Itk-/- PMCs were undetectable in 
the absence of IgE crosslinking, indicating that these cells are not spontaneously 
secreting cytokine.  Based on these findings, we speculate that enhanced 
cytokine production by Itk-/- mast cells in vivo may contribute to the spontaneous 
TH2-biased phenotype of the Itk-/- mouse, as indicated by elevated levels of IgE in 
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the serum and germinal center hyperplasia (63, 161, 166, 172).  Studies using a 
variety of experimental systems have shown that, in vivo, mast cells can 
influence the responses of B cells, T cells, and dendritic cells.  Further, mast cell-
derived cytokines have been shown to induce TH2 cytokine production by CD4 T 
cells in vitro.  
 The studies described here reveal a regulatory role for Itk in mast cell 
signaling that is in direct contrast to its function in T cells.  Our findings are also 
confirmed by a report by Iyer, et al. showing enhanced production of cytokines by 
Itk-/- mast cells stimulated through the FcεRI (75, 244).  This study, however, was 
unable to detect any biochemical defect in FcεRI-mediated signaling from mast 
cells lacking Itk.  Taken together these data provide strong support for a negative 
regulatory role for Itk in mast cells.  As Itk inhibitors are being developed for 
therapeutic purposes in dampening T cell responses, particularly in the context of 
atopic diseases, these studies underline the importance of considering 
contributions from other cells that express Itk.   
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Materials and Methods 
 
Mice 
 
C57BL/10 (B10) and Itk-/- mice (159, 173-176) (backcrossed to B10 for 13 
generations) were housed and bred in the pathogen-free animal facility at 
University of Massachusetts Medical School.  All mice were used in accordance 
with the Institutional Animal Care and Use Committee. 
 
Mast cells 
 
BMMCs were generated by culturing total bone marrow isolated from B10 or Itk-/- 
mice in RPMI-1640 supplemented with 10% FCS, 10% WEHI-3 conditioned 
supernatant, 100 U/mL penicillin, 100 ug/mL streptomycin, 100 mM L-glutamine, 
100 µM non-essential amino acids, 50 µM 2-ME, 10 µM HEPES buffer and 5-20 
ng/mL mouse rIL-3 (R&D Systems).  BMMCs were cultured at 1x106 cells/mL for 
4 weeks before maturation was determined by staining with anti-FcεRI FITC 
(eBioscience) and anti-c-Kit PE (BD Biosciences).  Flow cytometry was 
performed on a FACS Calibur or LSRII (both from BD Biosciences) and data was 
analyzed by FlowJo software (Tree Star).  BMMCs that were >95% FcεRI+ c-Kit+ 
were used for biochemical assays between 4-6 weeks in culture.  Additionally, 
primary mast cells from peritoneal exudate were isolated with anti-c-kit magnetic 
beads on an AutoMACS (Miltenyi Biotec) and analyzed as indicated.  The RBL-
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2H3 cell line were purchased from ATCC and cultured according to the supplier’s 
recommendations. 
 
Cell transfection 
 
293T cells were transfected with indicated plasmids using Lipofectamine 
Reagent (Invitrogen) according to the manufacturer’s instructions.  
 
Cytokine measurements 
 
Peritoneal mast cells were stimulated with plate-bound anti-IgE (Southern 
Biotechnology) for 20 hrs.  BMMCs were sensitized with anti-DNP IgE, either 
SPE-7 (Sigma) or H1-DNP-α-26 (purified H1-DNP-α-26 was a generous gift from 
Dr. Juan Rivera, the hybridoma cell line was kindly provided by Dr. F. T. Liu), in 
IL-3-free media for 4-6 hrs.  Cells were washed twice and incubated with DNP-
HSA (Sigma) for 20 hrs.  Cytokine release was detected by ELISA (IL-4, IL-6: BD 
Biosciences; IL-13: R&D Biosystems) or by Cytometric Bead Array (BD 
Pharmingen).  Cytometric bead array sample data were analyzed on an LSRII 
using the BD CBA Analysis Software 1 (BD Pharmingen).  
 
To assess cytokine mRNA, BMMCs were stimulated as described for cytokine 
release, but incubated with DNP-HSA for 4 hrs.  RNA isolation (Qiagen) and 
cDNA synthesis (Invitrogen) were performed according to manufacturer’s 
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instructions.  Primer sequences for RT-PCR were obtained from PrimerBank 
(http://pga.mgh.harvard.edu/primerbank/).  The following primer pairs (IDT), 
designated by PrimerBank ID, were used: IL-4: 10946584a1, IL-6: 13624311a1, 
IL-13: 6680403a2, β2 -microglobulin: 31981890a1.  Quantitative real-time-PCR 
was performed using conditions as indicated by PrimerBank, with FastStart 
SYBR Green Master (Roche) on an iCycler (Bio-Rad). 
 
Degranulation 
 
β-hexosaminidase release was performed essentially as described previously 
(177, 229).  Briefly, BMMCs were sensitized with 1 µg/mL IgE for 4-6 hrs then 
incubated with indicated doses of DNP-HSA for 30 min.  Supernatants and cell 
lysates were incubated with 1 mM p-NAG (Sigma) for 1 hr.  Na2CO3/NaHCO3 
buffer (0.1 M) was added and absorbance read at 405nm.  Percent degranulation 
was calculated as O.D. values of sup/(sup+pellet) X 100. 
 
Immunoblotting 
 
BMMCs were sensitized with 0.5-1 µg/mL IgE for 4-6 hrs in IL-3-free media, 
incubated with 100 ng/mL DNP-HSA as indicated, and lysed.  Proteins were 
resolved by SDS-PAGE, transferred to nitrocellulose (Schleicher & Schuell), and 
blotted with antibodies against Itk (178, 290), Btk, PLC-γ2, IκBα (Santa Cruz 
Biotechnology), p-PLC-γ1 (BioSource), PLC-γ1 (Upstate Biotech), p-PLC-γ2, p-
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ERK1/2, ERK1/2, p-IκBα, p-Src, p-p38, GAPDH, and PI3-kinase p85 (Cell 
Signaling Technology).  HRP-conjugated secondary antibodies (Sigma) and 
chemiluminescence reagents (Pierce) were used for detection.  Densitometric 
analysis was performed with NIH ImageJ software.   
 
Ca2+ flux 
 
BMMCs were sensitized with 1 µg/mL IgE for 4 hrs, washed, and incubated in 
RPMI-3% FBS containing 16 µM Fura Red and 16 µM Fluo-3 (Molecular Probes) 
for 45 min at 37˚C.  Cells washed in indicator-free media, resuspended in 
Tyrode’s-BSA, and further incubated for 30 min at room temperature.  Cells were 
analyzed by flow cytometry, with addition of DNP-HSA at 30 sec and ionomycin 
(Calbiochem) at 8 min.  Ca2+ mobilization was assessed as a ratio of Fluo-3/Fura 
Red fluorescence. 
 
NFAT assay 
 
NFATc1 ELISA (Active Motif) was performed according to manufacturer’s 
instructions.   
 
Confocal Microscopy 
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BMMCs from B10 WT or Itk-/- mice were seeded on Fibronectin (Sigma-Aldrich, 
1:50) coated coverslips, fixed in 2% paraformaldehyde, and permeabilized with 
0.025% saponin.  Cells were stained with primary antibodies against Itk (179-
181, 290), Shc, Dok-1, Dok-2, Grb-2, LAT, or JAK3  (Santa Cruz Biotechnology) 
for 16 hours at 4°C.  For co-staining, cells were incubated sequentially with two 
primary antibodies.  Cells were washed twice for 5 min and incubated with 
secondary antibodies (rabbit anti-mouse AlexaFluor 488, donkey anti-goat 
AlexaFluor 568) for 1 hr at 4°C.  Coverslips were mounted on microscope slides 
in 20 µL ProLong antifade mounting medium (Molecular Probes) and examined 
by confocal microscopy using a Leica SP1 laser scanning confocal microscope 
(Leica Microsystems).  
 
GST-pulldown 
 
GST fusion proteins were prepared as described previously (136, 182, 291).  The 
Itk GST-SH23* construct contains the tandem Itk SH2 and SH3 domains, each of 
which carries a single amino acid substitution that abolishes ligand binding to the 
canonical binding pockets (124, 183, 291).  Lysates from untreated or stimulated 
cells were incubated with the washed GST fusion matrices.  For the competition 
assay, an Itk SH2 domain specific phosphopeptide (AC-ADpYEPP-NH2) was 
pre-incubated for 30 min with the matrix prior to the pulldown (63, 184, 281).  For 
Western blots, membranes were probed with antibodies to SHIP-1 (P1C1, Santa 
Cruz Biotechnology). 
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Co-immunoprecipitation 
 
Transfected 293T cells were left untreated or were treated for 15 min with 
pervanadate (0.4 mM Na3Vo4, 0.04% H2O2) just prior to harvesting at 24 hrs 
post-transfection.  Immunoprecipitations were performed for 18 hrs with 2 µg 
anti-SHIP-1 antibody (clone P1C1, Santa Cruz Biotechnology) followed by 
Protein Agarose A+G (Santa Cruz Biotechnology) beads for 1 hr. 
Immunoprecipitates were washed in lysis buffer, boiled in sample buffer, and 
separated by 7.5% SDS polyacrylamide gel electrophoresis.  For Western blots, 
proteins were transferred onto nitrocellulose membrane and probed with anti-Itk 
antibodies (185-187, 290).  
 
Baculoviral expression 
 
Sf9 insect cells were obtained from ATCC.  Baculoviral stocks were generated 
using the Bac-to-Bac system (Invitrogen).  Sf9 cells were infected with viruses 
encoding wild-type Itk or the kinase-inactive Itk (K390R).  These cells were then 
co-infected with viruses expressing Dok-1, Dok-2, or SHIP-1 and incubated 72-
96 hrs prior to harvesting.  Membranes were incubated with antibodies against p-
Tyr (4G10 Platinum, Upstate Biotechnology), Dok-1 (Santa Cruz Biotechnology), 
Dok-2 (Santa Cruz Biotechnology), or Itk (188, 189, 290). 
  
 
 
 
 
 
 
 
 
 
Chapter 4: Discussion 
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Synopsis 
 
The theory of signal transduction describes a series of sequential steps in 
which an extracellular ligand induces chemical changes inside a cell.  This 
multistage process is initiated by ligation of a receptor embedded within a cell 
membrane and is potentiated, in part, by intracellular signaling kinases.  Itk is a 
non-receptor tyrosine kinase that facilitates signal transduction downstream of 
several multi-chain immune recognition receptors.  Since its discovery in the 
early 1990’s, hundreds of scientific reports have elucidated the biochemical, 
cellular, and physiological nature of Itk.  Biochemically, we understand how Itk is 
regulated and have identified several binding partners.  We know the 
hematopoietic expression of Itk and its primary function in signal transduction.  In 
a physiological sense, we are beginning to learn the role of Itk in several 
immunological processes.  Despite this plethora of information, there is still much 
that remains unknown about Itk.  This dissertation explores the behavior of Itk in 
the signal transduction of two cell types: T cells and mast cells.   
Chapter II expands upon the body of work that describes Itk as a positive 
regulator of T cell activation.  The data demonstrates that two types of signals, 
digital and analog, emanate from the TCR upon stimulation.  Digital signals are 
readily observed when T cells are stimulated with very potent TCR ligands, a 
concept that is easily found in the literature.  Less is known about the analog 
signals that a T cell generates.  When T cells see antigens that are less potent 
but able to overcome tonic signaling, an analog T cell response is revealed.  
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Altering the activity of signaling mediators such as Itk and NFAT can modulate 
the signals generated when a T cell encounters a strong ligand.  The significance 
of characterizing these two signals is underscored by the expression pattern of 
IRF4 and Eomes, two transcription factors important for the activation of CD8 T 
cells.  As such, we propose that Itk is responsible for the graded response of T 
cell activation.   
In contrast to the positive regulatory role that Itk plays in T cells, the role of 
Itk in mast cells is less understood.  The data in chapter III describes a unique 
function for Itk as a negative regulator of mast cell activation.  Mast cells lacking 
Itk, synthesize elevated levels of cytokines when stimulated through the FcεR1 
compared to their wild-type counterparts.  This hyperactivation of Itk-deficient 
mast cells correlates with enhanced and sustained signaling downstream of the 
FcεR1.  Interestingly, SHIP-1 is identified as a novel binding partner for Itk.  In 
this regard, we postulate that Itk participates in an inhibitory pathway that is 
responsible for dampening the de novo synthesis of cytokines. 
The two data chapters contain an individual discussion section that 
considers the direct implications of the data presented with respect to signal 
transduction.  This chapter attempts to expand upon those implications and 
further speculates about the physiological role that Itk has in both T cells and 
mast cells.  This chapter is divided into two sections, each dealing with the 
signaling characteristics and physiological aspects of Itk in T cells and mast cells.  
 
 
147
T cells 
 
As described earlier, Itk has been shown to regulate TCR-mediated 
signals through the phosphorylation of PLCγ1 (151-153, 189).  In turn, the 
second messengers IP3 and DAG invoke conserved signaling pathways required 
for gene expression and optimal cellular activation.  Precluding Itk function, either 
through genetic manipulation or pharmacological inhibition, severely disrupts the 
linkage between membrane proximal signaling events and major downstream 
pathways (159, 188).  Intriguingly though, TCR signal transduction is not 
completely ablated in the absence of Itk.  PLCγ1 still gets phosphorylated and 
gene transcription remains partially intact, albeit at a fraction of wild-type levels.  
Several questions immediately arise.  Why, then, is Itk needed at all?  In what 
manner does Itk modulate TCR signaling?  Does Itk favor one major pathway 
over another?  What transcriptional targets does Itk regulate?  What other factors 
are implicated in this regulatory process?  And finally, what are the cellular fates 
that Itk determines?   
The data contained in chapter II directly addresses several of these 
questions.  For example, one of the primary roles that Itk has is the modulation of 
TCR signal strength.  It does so by converting digital signals, presumably derived 
from Src and Syk family kinases, into analog responses.  A model that depicts 
the function of Itk in this capacity is described at the end of chapter II, Figure 2.7.  
Rather than reiterate the digital and analog manner in which Itk behaves 
downstream of the TCR, a more speculative examination of Itk in TCR signaling 
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and T cell responses will be discussed.  In accordance with this, two more 
models are proposed that illustrate the interrelated aspects that Itk plays in: 
1. TCR signal transduction. 
2. The physiological response of T cells. 
 
1. TCR signaling pathways 
 
 As mentioned previously, IRF4 expression is sensitive to the effects of Itk 
activity.  Currently, it is not clear how IRF4 expression is regulated in CD8 T 
cells.  Although we have implicated an NFAT-mediated pathway in graded IRF4 
expression, it’s uncertain as to whether other signaling pathways could be 
responsible for transducing analog signals.  It is currently accepted that the NF-
κB pathway transduces digital signals from the TCR to induce gene expression of 
targets like TNF and CD44 (190, 265, 292).  The MAPK pathway possesses 
features of analog and digital activation but it is believed that the analog 
components of this pathway exist to switch the signal to a digital one (191, 249).  
By and large the contention in the field is that the MAPK pathway, notably Erk1/2, 
are partially responsible for digital activation of T cells (192, 193, 263, 293, 294).   
An intriguing proposition then remains that the Ca2+ pathway could display 
analog characteristics.  One of the more profound defects associated with Itk 
deficiency lies in its relationship with Ca2+ mobilization and NFAT activity (159, 
194).  Specifically, Itk-deficient T cells stimulated through the TCR display an 
intermediate level of Ca2+ mobilization compared to wild-type T cells and 
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unstimulated T cells.  This suggests the existence of an implicit sensitivity of this 
pathway to Itk activity, and by extension to TCR signal strength.  Hence, it came 
as no surprise to us that the NFAT inhibitor experiments essentially phenocopied 
the Itk inhibitor experiments in chapter II.  These initial experiments conducted in 
chapter II have revealed that limiting the activity of NFAT by titration of the 
inhibitor yields graded IRF4 expression when CD8 T cells are stimulated with 
various peptides.  This suggests that an NFAT-mediated pathway is capable of 
transmitting an analog signal from the TCR to the nucleus where induction of 
genes like Irf4 will occur.  At this time we are unsure whether graded Ca2+ 
mobilization is involved in our system.  James Conley, in our lab, has planned 
two types of complementary experiments to address this issue.  The first 
experiment involves the titration of the calcium ionophore ionomycin.  Here, CD8 
T cells will be stimulated with or without APLs in the presence of decreasing 
amounts of ionomycin.  If Ca2+ mobilization can transduce analog signals then 
cells stimulated without additional TCR signals (ionomycin alone) should display 
graded IRF4 expression.  Alternatively, if we see bimodal IRF4 expression it 
would suggest that other signals are required to cooperate with the Ca2+ pathway 
to generate intermediate levels of IRF4.  These other signals would likely be 
resolved in the presence of TCR stimulation.  A second type of experiment will 
use a calcium chelator, EGTA, to limit the availability of free calcium in the 
media.  This will effectively change the extracellular calcium concentration and 
the amount of store operated calcium entry (SOCE) in stimulated cells can be 
controlled.  This approach brings the added advantage of not bypassing 
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components of the TCR signaling cascade.  Calcium chelation using increasing 
amounts of EGTA is expected to result in the graded expression of IRF4 when 
CD8 T cells are stimulated through the TCR.  If neither of these experiments 
reveals an analog response, then another possibility is that NFAT activity can be 
induced in a Ca2+-independent manner.  Ca2+-independent NFAT activation has 
been demonstrated in cardiomyocytes in response to leptin-mediated signaling 
(75, 295).  Therefore it remains a possibility that CD8 T cells use similar signaling 
machinery to induce Ca2+-independent NFAT activation.   
Our data do not distinguish between the possibilities of direct or indirect 
regulation of IRF4 by NFAT.  Preliminary analysis of the IRF4 proximal promoter 
has identified several putative binding sites for the transcription factor NFAT.  
Future chromatin immunoprecipitation experiments have been planned to 
investigate the direct regulation of IRF4 by NFAT.  However, given what is known 
about the regulation of IRF4 expression in other cell types, it is unlikely that 
NFAT participates in this process alone.  In B cells for example, IRF4 expression 
is induced by a combination of BCR stimulation and IL-4 signaling, which in turn 
activate the transcription factors NF-κB and STAT6, respectively (194, 296, 297).  
This is thought to lead to the graded expression of IRF4 in B cells (63, 298).  
Indeed, our analysis also identified STAT6 binding sites in the promoter as a 
potential candidate in the regulation of IRF4.  However, both published and 
unpublished data from our lab indicates that when CD8 T cells are stimulated 
through the TCR in the presence of IL-4, IRF4 expression levels do not change 
(177, 259).  It remains to be seen whether other cytokine signaling pathways can 
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synergize with TCR signaling to induce IRF4.  It is a possibility that multiple 
pathways downstream of the TCR cooperate for full IRF4 expression.  One report 
has suggested that the NF-κB pathway can induce transcriptional changes of Irf4 
in lymphocytes (195, 297).  The potential for NF-κB to cooperate with NFAT is 
not novel, as they have both been linked to IL-2 transcription (196-200, 299).  
Future experiments in our lab will explore the cooperativity of multiple TCR-
induced signaling pathways in the regulation of digital and analog responses.  
Nonetheless, we propose a model, illustrated in Figure 4.1, for T cell signaling 
that incorporates currently published theories described above with our own data.  
 
2. The physiological response of T cells 
 
One other aspect of our results on TCR signal strength deserves attention.  
Our experiments fail to directly test the immunological influence that TCR signal 
strength may pose.  However, the literature is replete with examples of 
physiological processes using the exact cells and epitopes we have used.  All of 
these processes are regulated by currently unexplained mechanisms; we feel 
that our data provides such a mechanism.  Two specific examples will be 
discussed with respect to our data. 
In a report published in Nature, Zehn and colleagues utilize an infection 
model that changes epitopes specific for CD8 T cells in order to study the 
immune response to Listeria monocytogenes (201-203, 247).  Although all T cells 
respond
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Figure 4.1 
 
 
 
 
Figure 4.1 Model for T cell receptor signaling 
TCR ligation (an analog input) leads to the recruitment and activation of PTKs at 
the plasma membrane.  Digital conversion of the signal occurs by PTKs like Lck 
and ZAP-70.  DAG-mediated pathways display digital activation and induce 
digital responses (88, 195, 204, 249).  Concurrently, Itk can modulate the digital 
signal, which is dependent on the strength of the initial input, like a rheostat, 
thereby generating an analog signal.  The analog signal then emanates through 
NFAT producing the graded expression of target genes. 
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to the initial challenge, they do so with dissimilar kinetics and magnitude.  The 
initial rate of proliferation of CD8 T cells responding to high and low potency 
ligands is similar amongst the two cell populations.  However the expansion of 
cells primed in response to low potency epitopes peaks two days earlier, at day 
5.5, than those cells exposed to higher potency epitopes.  Moreover, cells 
exposed to low potency ligands leave the draining lymph nodes prematurely and 
undergo contraction much earlier than cells exposed to strong TCR ligands.  This 
implies that TCR signal strength is not important for the initial proliferative burst 
associated with CD8 T cell clonal expansion, but rather for the total amount of 
expansion, lymph node retention, and onset of contraction.  Data from our lab 
indicates that CD8 T cells stimulated with APLs undergo similar proliferation out 
to 4 days in culture.  This is consistent with what the authors observed in vivo.  
The findings in this report also demonstrate that the cells exposed to low potency 
ligands display a similar cell surface phenotype compared to those exposed to 
high potency ligands.  This is the exact result that we see in vitro.  The authors 
did not examine the transcription factor profile and therefore were unable to 
properly decipher the differentiation pathways that CD8 T cells undergo in 
response to a pathogen.  We suspect, though, that more IRF4 would be seen in 
cells stimulated in the presence of strong TCR ligands, whereas those cells 
stimulated with weak TCR ligands would display low levels of IRF4.  Here is 
where an interesting dichotomy occurs with our data.  In contrast to the 
phenotype associated with IRF4 expression levels, we see an inverse 
relationship with Eomesodermin (Eomes).  That is, weak signals from the TCR 
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induce more Eomes expression than strong signals.  Our lab has recently 
published data suggesting that IRF4 can negatively regulate the expression of 
Eomes in CD8 T cells (205, 259).  Given the importance of Eomes expression 
levels in determining the fate of CD8 T cell differentiation in response to infection, 
it is tempting to speculate that this might be regulated, in part, by IRF4.  Ribhu 
Nayar and Beth Schutten, in our lab, are currently performing experiments to 
address the role of IRF4 in the response of CD8 T cells to LCMV.  Thus far, 
these studies seem to indicate an important role for IRF4 in the generation of 
short-lived effector cells (SLEC), as mice infected with LCMV in the absence of 
IRF4 have about one third as many responding cells compared to wild-type.  
Taken together, we postulate that the strength of TCR stimulation received by a 
CD8 T cell has a direct influence on the outcome of differentiated T cells.  We 
further propose that this outcome is regulated by the analog signals, mediated by 
the activity of molecules such as Itk and NFAT, which originate from the TCR. 
In a second example recently published in Immunity, King and colleagues 
demonstrate the importance of TCR signal strength in mediating cell division of 
CD8 T cells (204, 246).  Cells receiving stimulation from highly potent ligands 
undergo asymmetric cell division.  These cells sustain long-lasting T cell - APC 
conjugates and undergo substantial proliferation.  Asymmetry is demarcated by 
CD8 expression, where proximal daughter cells receive the most amount of CD8, 
while distal daughter cells receive less CD8.  Interestingly the proximal daughter 
cells exhibit a phenotype resembling SLECs.  In contrast to cells stimulated with 
strong TCR signals, cells receiving stimulation from less potent ligands undergo 
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symmetric division, do not have as long a contact time with an APC, and don’t 
proliferate as much.  The proliferation results are somewhat at odds with Zehn 
and colleagues but this is likely due to variation in the design and time points 
used in the in vivo system.  In vitro, it is clear that cell division is influenced by 
TCR signal strength.  Furthermore, it has previously been shown that asymmetric 
division is a key determinant in the differentiation of CD8 T cells in vivo (101, 
205-207).  Here, progeny of CD8 T cells that have divided asymmetrically are 
differentially marked by Eomes and T-Bet segregation.  The authors in the 
current study fail to examine the transcription factor profile of daughter cells.  
Based on our data, however we would predict that cells receiving strong signal 
strength would express the least amount of Eomes and the most amount of IRF4.  
This is consistent with the idea that SLECs express less Eomes than their 
counterparts, memory precursor effector cells (MPECs).  
 In conjunction with our data, the two physiological examples described 
help us construct a more complete model for CD8 T cell differentiation.  This 
model is depicted in Figure 4.2.  We propose that cells receiving strong TCR 
signals will exhibit high levels of Itk activity, induce more IRF4, and promote the 
formation of SLECs.  On the other hand, cells that receive weak TCR signals 
exhibit lower levels of Itk activity, induce more Eomes, and promote the formation 
of MPECs.  
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Figure 4.2 
 
 
 
 
 
Figure 4.2 Physiological implications of altering TCR signal strength 
T cell stimulation with ligands that induce strong signals result in high Itk activity, 
which generates copious amounts of IRF4. IRF4 represses Eomes expression.  
The immunological outcome is prolonged T cell:APC interactions and retention in 
the LN, asymmetric division, and differentiation of short lived effector cells (208, 
300).  T cells stimulated with weaker ligands do not impose as much Itk activity 
and therefore do not express high levels of IRF4.  Low levels of IRF4 allow for 
high amounts of Eomes.  This results in short T cell:APC contacts and early exit 
from LNs.  Unpublished data from our lab suggests these cells become memory 
precursor effector cells. 
  
157
Mast cells 
 
 In contrast to T cells, far less information is known about the role of Itk in 
mast cells.  Although Itk is activated and recruited to the membrane upon 
crosslinking of the FcεR1, substrates for Itk have not been identified inside mast 
cells.  A similar Tec family kinase, Btk, is also expressed in mast cells.  The role 
of Btk in mast cells has been extensively studied.  Btk-deficient mast cells have 
defects in all aspects of mast cell activation, including reduced cytokine 
expression and reduced degranulation.  This phenotype is accompanied by a 
reduction in the activation of key signaling molecules, such as PLCγ, a major 
substrate for Btk.  These defects highlight the importance of Btk in transducing 
FcεR1-mediated signals.  The conclusion is that Btk is a positive regulator of 
mast cell activation.   
The data in chapter III demonstrates that mast cells lacking Itk are 
hyperresponsive when activated through the FcεR1.  This is shown by the 
increased levels of cytokines and enhanced signaling downstream of the FcεR1.  
We have proposed that Itk is involved in an inhibitory pathway that is regulated 
by the phosphatase SHIP-1.  Another interesting observation in chapter III is the 
ex vivo phenotype of mast cells from Itk-deficient mice.  Here, mast cells show 
elevated expression of FcεR1 on the cell surface.  When these cells are 
stimulated by crosslinking the FcεR1, they produce more IL-4 and IL-13.  The 
remainder of this chapter focuses on two major themes.  First, the results from 
two major studies investigating the contribution of Itk-deficient mice in allergic 
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airway hyperresponsiveness are reconciled.  These results are then linked to our 
results to form a model for the role Itk and Btk in mast cell activation.  Finally, a 
speculative role for mast cells is attributed to one of the major unresolved 
phenotypes in Itk-deficient mice. 
 
1. Itk limits the responsiveness of mast cells in the airway through an inhibitory 
pathway 
 
 The few studies of Itk in mast cells have been less fruitful and have 
generated contradicting conclusions.  An initial report from Forssell and 
colleagues, concluded that mast cells in Itk-deficient mice have an important role 
in mediating immediate and late-phase allergic responses in vivo (209, 241).  
Compared with Btk-deficient mice, Itk-deficient mice displayed greater protection 
to an airway allergen challenge as demonstrated by a lack of plasma leakage 
into blood vessels.  Examination of mast cells in the lungs of Itk-deficient mice 
revealed that this result was due to a severe impairment in the ability of cells to 
degranulate in response to the aerosolized allergen.  These findings suggest that 
Itk strongly promotes mast cell degranulation in immediate airway 
hypersensitivity.  The authors also looked for signs of inflammation in the airways 
by examining leukocyte infiltration.  This is a hallmark of late-phase 
hypersensitivity, which occurs many hours after allergen challenge.  In 
comparison to wild-type and Btk-deficient mice, Itk-deficient mice had very few 
cellular infiltrates in the lung tissue or bronchoaveolar lavage (BAL) fluid.  The 
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authors concluded that Itk-deficient mast cells failed to promote inflammation 
because of an inability to generate the TH2-cytokines required for chemotaxis 
and extravasation.  These results further implicate Itk as an important mediator of 
airway hypersensitivity.   
This paper was important for two reasons.  First, it recapitulated many of 
the results seen in Btk-deficient mice and second, it ascribed a function for Itk in 
mast cells.  One of the major faults with this study, though, is that Itk-deficient 
mice have an inherent inflation of circulating IgE within them (166, 210), and 
mast cells are sensitive to the amounts of IgE in the microenvironment.  Mast 
cells acquire unbound IgE in the periphery by extending cellular projections 
through the walls of the blood vessels (191, 301).  Upon sampling the 
environment, IgE is then bound by FcεR1 until a specific allergen or antigen can 
crosslink the receptors.  Although the specificity of IgE antibodies in Itk-deficient 
mice is unknown, it is unlikely that they recognize the sensitizing allergen in this 
case.  Moreover, the amount of available IgE has been shown to regulate mast 
cell proliferation, survival, and functionality (191, 211, 302).  Consistent with this 
notion, our data has shown that the amount of IgE in the serum also influences 
the level of IgE receptor on the cell surface of mast cells.  This is unsettling 
because the corresponding wild-type mast cells have fewer FcεR1 molecules per 
cell, giving Itk-deficient mast cells an unfair advantage in signal transduction.  
The other major caveat in this report is the model of hypersensitivity used.  The 
authors chose to inject a mixture of ovalbumin and aluminum hydroxide as a way 
to sensitize and challenge mast cells.  However, the cellular reactivity to this type 
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of allergen is not limited to mast cells (212, 303).  Both antibody responses and T 
cell reactivity can play an important role in the immunological response to 
allergens in this hypersensitivity model.  Itk-deficient mice, as far as we know, do 
not have any major developmental or functional defect in the B cell compartment.  
As documented several times in this dissertation, the T cell compartment is 
heavily skewed in these mice and functionality is impaired.  For the reasons 
presented, the complete significance of Itk in the function of mast cells in this 
system is unclear. 
A second group chose a different approach to examine the role of Itk in 
acute airway responsiveness (191, 244).  Itk-deficient mice were sensitized with 
an anti-hapten IgE antibody.  Aerosolized exposure to the hapten resulted in 
diminished airway responsiveness compared to wild-type mice when challenged 
with methacholine.  This was attributed to defective release of histamine and is 
consistent with Forssell and colleagues.  However, like our data shows, Iyer and 
colleagues also demonstrate that mast cells in Itk-deficient mice have elevated 
levels of IgE receptor on the cell surface.  To bypass this caveat, they chose to 
incorporate an in vivo reconstitution model where wild-type or Itk-deficient 
BMMCs were adoptively transferred into mice lacking mast cells.  When airway 
responsiveness was examined, mice reconstituted with Itk-deficient BMMCs 
responded the same way as wild-type controls.  This indicates that in vivo, Itk is 
not necessary for mast cell degranulation.  This correlates with our observation 
that Itk-deficient BMMCs do not have any noticeable degranulation defect in vitro.  
When Iyer and colleagues examined cytokine production in BMMC lacking Itk, 
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they observed increases in IL-2, IL-4, IL-13, TNF, and GM-CSF compared to 
wild-type BMMCs.  The data in this dissertation support this observation and take 
it several steps further.  Since mast cells can potently release preformed 
mediators, including cytokines like IL-4 and TNF, we wanted to determine 
whether this defect was from de novo synthesis (35, 65, 211, 213).  We show 
that, in accordance with elevated protein levels, transcripts for the indicated 
cytokines were also increased in Itk-deficient mast cells.  Our data implies that 
Itk-deficient mast cells do indeed have a signaling abnormality.  Admittedly, when 
we look at early time points proceeding FcεR1 stimulation in Itk-deficient mast 
cells, we note only a mild signaling impairment.  This is highlighted in the 
activation of PLCγ and is accompanied by a slight increase in Ca2+ mobilization 
and increased NFAT activity.  Similarly, Iyer and colleagues also detect 
increased localization of NFAT in the nucleus of Itk-deficient mast cells.  This is 
perplexing because they do not observe a single signaling defect in these cells.  
In fact, in some of their experiments they noticed some signaling components 
were diminished when compared to wild-type BMMCs.  Nonetheless, the 
substantial elevation in cytokines we have both observed do not seem to fit with 
the signaling data.  We rationalized that because the major defects observed in 
Itk-deficient mast cells were during the second wave of activation, perhaps we 
were not looking at the correct time points.  We attempted to unravel this 
disconnect by inspecting the status of signaling molecules at much later time 
points following FcεR1 stimulation.  Much to our surprise, Itk-deficient BMMCs 
not only displayed elevated levels of activated signaling molecules but they were 
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also sustained several hours following stimulation.  Our data substantiates a 
bona fide signaling defect in response to FcεR1-mediated stimulation and 
suggests that Itk is a negative regulator of mast cell activation. 
Negative regulation of FcεR1-mediated mast cell activation is facilitated by 
several signaling molecules including kinases (e.g. Lyn), phosphatases (e.g. 
SHIP), and adaptor proteins (e.g. Dok).  One of the major inhibitory pathways 
that mast cells use to shutdown FcεR1-induced signaling is regulated by SHIP-1.  
This pathway is initiated by Lyn phosphorylation of SHIP-1, which upon 
activation, translocates to the membrane where phosphatase activity can 
catalyze the conversion of PIP3 to PIP2 (208, 304).  Activation of SHIP-1 triggers 
the assembly of a larger complex containing adaptor proteins such as Dok1, Shc, 
and Grb2 that bind to the C-terminal domain of SHIP-1 (214, 305).  Interestingly, 
mast cells lacking SHIP-1 or Dok1 exhibit a strikingly similar phenotype to Itk-
deficient mast cells with one notable exception (208, 215, 279, 306).  The 
amount of degranulation is about 4-fold higher in mast cells lacking SHIP-1 
compared to wild-type controls.  The other enticing piece of information was that 
the Tec family kinase, Tec, has been reported to associate with SHIP-1 via the 
SH3 domain in T cells (126, 216).  A number of our biochemical experiments 
demonstrated a specific interaction between Itk and SHIP-1, mediated by the 
SH2 and SH3 domains of Itk.  This was somewhat surprising because it had 
previously been reported that the SH3 domain of Itk did not bind to SHIP-1 in T 
cells (10, 126).  Given the promiscuity attributed to SH3 domains in general, a 
likely explanation for this discrepancy is that other proteins not expressed in mast 
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cells occupied the SH3 domain of Itk.  Nonetheless, the interaction we observed 
by the SH2 domain of Itk appeared to be specific because competitive inhibition 
or mutation of this domain ablated SHIP-1 association.  Using confocal 
microscopy, we were also able to demonstrate co-localization of Itk with several 
members of the negative regulatory complex that SHIP-1 nucleates.  The 
significance of SHIP-1 phosphorylation by Itk is unclear at the moment.  Due to 
technical limitations, we have only been able to demonstrate phosphorylation in 
insect cells.  Taken together, the biochemical data and microscopy suggest that 
Itk forms a novel interaction with a known negative regulatory complex in mast 
cells.   
Given the data presented in this dissertation, in conjunction with the 
available information in the literature, we propose the model in Figure 4.3.  Upon 
FcεR1-mediated activation of mast cells, Tec family kinases translocate to the 
plasma membrane to regulate signal transduction.  Btk is responsible for the 
phosphorylation of PLCγ, which propagates the activating pathway in mast cells.  
Concomitantly, Itk associates with a macromolecular complex containing SHIP-1 
to participate in the inhibition or dampening of FcεR1 signal transduction.  The 
presence of both of these kinases is required for optimal mast cell activation. 
 
2. Mast cells contribute to the TH2 phenotype in Itk-deficient mice 
 
 One of the initial phenotypes described in Itk-deficient mice was the 
existence  of  a  spontaneous TH2-like environment (161, 217).  This environment  
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Figure 4.3 
 
 
 
 
 
Figure 4.3 Itk negatively regulates mast cell activation  
Crosslinking the FcεR1 results in the induction of gene transcription through 
activating pathways regulated by Btk.  Concurrently, inhibitory pathways, 
mediated by Itk, turn down or dampen the de novo synthesis of mast cell 
products like cytokines. 
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displays extremely high levels of TH2-associated antibodies (IgG1 and IgE) in the 
serum and germinal center B cell hyperplasia.  This phenotype is greatly 
exacerbated in mice doubly deficient for Itk and Rlk.  In order for B cells to class-
switch and secrete IgE they must be exposed to IL-4 and IL-13 (218-220, 307).  It 
was found by Catherine Yin, a former graduate student in our lab, that γδ T cells 
from Itk-deficient mice have a skewed cytokine profile compared with wild-type 
γδ T cells.  A specific subset of γδ T cells normally associated with their ability to 
make TH1-associated cytokines, like IFNγ, begins making copious amounts of IL-
4 upon TCR stimulation.  She further found a vast increase in the total numbers 
of this γδ T cell subset in Itk-deficient mice.  These two observations were 
attributed to a developmental abnormality in the γδ T cell subset caused by a 
lack of Itk (10, 308).   
Interestingly, when Itk-deficient mice are crossed to mice lacking γδ T 
cells, the progeny have reduced levels of IgE in the serum and are largely 
rescued from the TH2-like phenotype (166, 221).  However, a complete rescue is 
not observed as a significant amount IgE (about 5-fold higher than wild-type) 
remains in the circulation.  Furthermore, B cell germinal center hyperplasia is not 
completely restored to wild-type levels.  Intriguingly, the TH2 phenotype in the 
Itk/Rlk double knockout mice is not rescued by a cross to mice lacking γδ T cells 
(our unpublished observations).  This indicates that γδ T cells are not the only 
cell type that contributes to the TH2-like environment.  Because of the enhanced 
cytokine production, specifically IL-4 and IL-13, associated with mast cells 
lacking Itk, it remains plausible that this cell type is partially responsible for this 
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phenotype.  The other interesting facet of the data in chapter III, is that Itk-
deficient mast cells that are exposed to IgE alone are hyperresponsive and 
secrete more cytokines than wild-type mast cells.  This suggests that even in the 
absence of antigen, mast cells lacking Itk can secrete IL-4 and IL-13 into the 
local environment.  These cytokine can then instruct B cells to class switch to IgE 
and generate the extremely high levels seen in Itk-deficient mice.  The access 
IgE can in turn reactivate cytokine production in mast cells, thereby forming a 
positive feedback loop.  It is therefore postulated that mast cells contribute to the 
spontaneous TH2-like environment in Itk-deficient mice by promoting a 
continuous IL-4/IL-13 - IgE cycle (Figure 4.4).  
 
Concluding remarks and significance 
 
 One major question that remains is - why does Itk behave so differently in 
T cells compared to mast cells?  The answer may lie in the examination of the 
major substrate of Itk that is available in each cell type and the presence of other 
Tec kinase family members.  In T cells, three Tec family kinases exist: Itk, Rlk, 
and Tec.  Ablation of Itk in T cells leads to a diminished TCR signaling.  Similarly, 
Rlk-deficient T cells also have decreased T cells signaling, albeit not as severe 
as Itk-/- T cells.  Tec-deficient T cells have the mildest impairments in signaling, 
and Tec-deficient mice are phenotypically normal.  T cells that are doubly 
deficient in Itk and Rlk have an extremely severe impairment in TCR signaling, 
and  exacerbated  defects  in  T  cell  development  and  function.    These  facts  
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Figure 4.4 Mast cells contribute to the TH2 phenotype in Itk-deficient mice  
Itk-deficient mice have an inherent TH2-like environment within them.  This 
phenotype occurs spontaneously without any intervention or manipulation.  The 
phenotype is marked by elevated levels of IgE in the serum.  Itk-deficient mast 
cells produce enhanced amounts of IL-4 and IL-13 in response to FcεR1 
crosslinking.  A positive feedback loop is therefore in place in which mast cells 
produce IL-4 and IL-13 that induces B cells to secrete IgE that bind to and 
activate more cytokine production from mast cells. 
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indicate the potential for functional redundancy amongst Tec family kinases, such 
that in the absence of one Tec family kinase another can lessen the defect by 
acting on the substrate.  The major substrate of Itk in T cells is PLC-γ1; a closely 
related molecule, PLC-γ2, is not expressed in T cells.  The expression level of Itk 
is many fold higher than Rlk or Tec, and this likely gives it a competitive 
advantage by simple stoichiometry for PLC-γ1 over the other Tec family kinases.  
This indicates that Itk is free to participate in the nucleation of the LAT complex 
and phosphorylate PLC-γ1 upon TCR ligation. 
 Interestingly, a synonymous situation occurs in B cells.  B cells express 
Btk at very high levels and Tec at very low levels.  In B cells, Btk has been shown 
to be the primary regulator of PLC-γ2; PLC-γ1 is not expressed in B cells.  
Similar to T cells, B cells deficient in Tec or Btk have defects in BCR signaling, 
with Btk deficiency exhibiting a more severe phenotype than Tec-/- B cells.  
Double deficient cells experience an even greater defect in BCR signaling, again 
suggesting a compensatory role for Tec family kinases in immunoreceptor 
signaling.     
 Mast cells, on the other hand, have components of both B cell signaling 
and T cell signaling.  That’s to say that many of the proteins that are exclusively 
found in B cells or T cells are found together in mast cells.  For example, mast 
cells express both Itk and Btk at very similar levels.  Furthermore, their 
substrates PLC-γ1 and PLC-γ2 are also co-expressed.  This is where the notion 
of functional redundancy breaks down, however.  As shown in chapter three, 
mast cells that lack Itk have the opposite phenotype as mast cells lacking Btk.  
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This is exemplified by the enhanced signaling that occurs downstream of the 
FcεR1 in Itk-deficient mast cells; Btk-deficient mast cells, on the other hand, have 
a severe reduction in the amount of signaling that occurs in response to FcεR1 
stimulation.  Perplexingly, PLC-γ1 phosphorylation is notably enhanced in the 
absence of Itk.  It is thought that Btk is capable of phosphorylating both PLC-γ1 
and PLC-γ2 in order to propagate signal transduction. Since, Itk and Btk are 
expressed at similar levels, it is unlikely that the enzyme – substrate 
stoichiometry is a factor.   The likely explanation for this conundrum lies in the 
catalytic activity of each kinase.  Btk has been shown to have enhanced 
enzymatic activity for substrate when directly compared to Itk (309).  
Furthermore, it is also possible that minor variations in peptide sequence within 
the kinase domains of Btk and Itk allow Btk to bind substrate with a greater 
propensity than Itk.  This is not to say that Itk is inferior.  In fact, the defects 
associated with Itk deficiency have been aptly described and it’s function should 
be further investigated. 
 Given the many immunological processes that Itk can partake in, it is an 
attractive target for therapeutic intervention.  The development of pharmaceutical 
inhibitors targeting Itk has found traction in several private companies for the 
treatment of human disorders mediated by the immune system (37, 310).  
Selective inhibition of Itk has been proposed as novel means for the treatment of 
HIV and skin inflammation disorders like atopic dermatitis (222, 311, 312).  A 
large majority of the research on Itk has been done in T cells and its function has 
been well characterized.  Our own studies have determined that Itk subtly 
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modulates T cell receptor signaling by tuning signal strength.  In light of this, we 
agree that targeting Itk could potentially work for a variety of diseases.  However, 
the data and commentary in this dissertation expand the functional role of Itk in 
the signal transduction of immunoreceptors.  The novel phenotype ascribed to 
mast cells lacking Itk cannot be ignored, especially when thinking about skin 
disorders.  We caution those interested in exploring Itk inhibition in the clinic.  
The novelty of Itk must also be considered in natural killer cells, where Itk is the 
predominant Tec family kinase expressed.  We have virtually zero knowledge on 
the role of Itk in this cell type.  Finally, the importance in understanding Itk has 
become even more pressing in recent years now that a cohort of people with 
genetic mutations in Itk has been found (157, 223).  Unfortunately, these people 
typically do not fair very well when Itk function is ablated and succumb to EBV-
linked infections.  Further inquiry into the pathogenesis of Itk deficiency must be 
performed.  I am confident that future investigation of Itk, in our lab and others, 
will address the outstanding issues surrounding Itk. 
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